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7ABSTRACT
Background: Soft tissue sarcoma (STS) is
a relatively rare mesenchymal malignan-
cy, that may occur almost anywhere in
the human body; the most common
sites, however, are the limbs. STS has an
infiltrative growth pattern, and local re-
currence of the disease after surgical
treatment is common. STS typically dis-
seminates haematogenously, most fre-
quently in the lungs. Although the death
of a patient with STS is usually due to
distant metastases, local recurrence caus-
es abundant morbidity and may lead to
mutilating operations. The prevention
and prediction of local recurrence are
therefore an important goal. STSs of the
extremities were traditionally managed
by amputation. Today, however, a combi-
nation of limb-salvage surgery with radi-
otherapy has proved to be as effective as
amputation in local control. The modern
combined modality treatment and chal-
lenging diagnostics have prompted the
need for multidisciplinary treatment
groups. One such group was established
at Helsinki University Central Hospital
(HUCH) in 1988. Dermatofibrosarcoma,
which has distinctive and more benign
features than other types of STS, is ex-
cluded from the STS treatment protocol.
Extensive plastic surgical reconstructions
are frequently needed in the treatment of
STS. In addition to the extremities, a
common site for the occurrence of a ma-
lignancy requiring plastic surgical recon-
structions is the chest wall, where the
majority of the tumours are sarcomas or
breast cancer recurrences.
Materials and Methods: The results of
our STS treatment protocol are evaluat-
ed in a series of 186 patients with STS in
an extremity. The gross and microscopic
margins and the results of surgical treat-
ment for 40 patients with dermatofibro-
sarcoma are studied, and guidelines for
treatment are sought. The results of the
management of full-thickness chest wall
resections with microvascular recon-
structions in 26 patients are also evaluat-
ed. As local recurrence poses a problem
in the treatment of STS, the genetic
changes occurring between primary tu-
mours and their subsequent local recur-
rences are studied in 20 patients by com-
parative genomic hybridisation (CGH).
All plastic surgical reconstructions re-
quired in the treatment of these muscu-
loskeletal malignancies are reported,
with special reference to microsurgical
techniques used in the chest wall.
Results: For extremity STSs, the 5-year
local recurrence-free survival rate was
79%, the metastasis-free survival rate
70% and the disease-specific overall sur-
vival rate 76%. Ninety per cent of these
patients were treated by limb salvage.
The strongest factor predicting local re-
lapse was extra-compartmental tumour
location. In the patients with dermatofi-
brosarcomas, there were no local or dis-
tant recurrences or amputations, with
average microscopic tumour-free mar-
gins of 1.6 cm. In patients requiring full-
thickness chest wall resection, the 5-year
survival rate was 28% for sarcomas and
13% for breast cancer recurrences; no
operative mortality or flap losses oc-
curred. The increase in genetic changes
from primary to locally recurrent STS
was detected by CGH, although no alter-
ation specific for local recurrence was
found. Plastic surgical reconstructions
were required in 53% of all patients. The
success rate for free flaps was 96.4%.
Conclusions: The treatment protocol of
HUCH for STS is functioning well. Tu-
mours located extracompartmentally
should be the main target of efforts to
improve treatment strategies. In the ma-
8jority of patients with dermatofibrosar-
coma, good local control can be achieved
by plain surgical excision in one opera-
tion. Owing to tumour progression, local
recurrences show an increased amount
of genetic changes compared to primary
STS. Reconstructive plastic surgical pro-
cedures, including free flaps, have a high
success rate and are frequently needed.
Large microvascular reconstructions for
full-thickness chest wall defects can be
performed with acceptable results. The
treatment of malignant musculoskeletal
tumours often requires plastic surgical
reconstructions.
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AIDS acquired immunodeficiency syndrome
CGH comparative genomic hybridisation
CNB core needle biopsy
COL1A1 collagen type I alpha-1
CT computed tomography
DFS disease-free survival
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DSOS disease-specific overall survival
EBV Epstein-Barr Virus
FFCC French Federation of Cancer Centers
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HHV 8 human herpes virus 8
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LRFS local recurrence-free survival
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MFS metastasis-free survival
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MRI magnetic resonance imaging
NCI National Cancer Institute
NF 1 neurofibromatosis type 1
OS overall survival
PDGF platelet-derived growth factor
PNET primitive neuroectodermal tumour
PTFE polytetrafluoroethylene
RT radiotherapy
SSG Scandinavian Sarcoma Group
STS soft tissue sarcoma
TFL tensor fasciae latae
TNF-α tumour necrosis factor alpha
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US ultrasonography
VRAM vertical rectus abdominis muscle
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INTRODUCTION
Soft tissue sarcoma (STS) is a relatively
rare cancer that can occur in almost any
site of the body. Unlike many other ma-
lignant neoplasms, it has various histo-
logical types and malignancy grades.
Throughout history, this heterogenic na-
ture of STS has caused difficulties in di-
agnostics and treatment. Formerly, STS
was managed by amputation in nearly
half of the patients. However, advances
in radiotherapy (RT) and its application
in conjunction with conservative surgery
created a limb salvage treatment modali-
ty, and amputation rates began to fall.
The increasing co-operation between
specialities, the infrequent nature of
these tumours, and the special problems
involved in diagnosis created a need for
multidisciplinary teams in which ade-
quate diagnostics and treatment could
be planned within the expertise of a pa-
thologist, molecular genetic, radiologist,
oncologist and surgeon familial with the
tumours.
Just such a team, the soft tissue sar-
coma group was established at Helsinki
University Central Hospital (HUCH) in
1988, and a treatment protocol that fa-
voured limb salvage treatment and the
selective combination of surgery and
RT, depending on the postoperative mar-
gins achieved, was developed. The group
meets once a week and plans the treat-
ment of STS patients, who are referred
from all over Finland. Scientific co-oper-
ation with the Scandinavian Sarcoma
Group is close. In addition to patients
with sarcomas, some with other muscu-
loskeletal tumours calling for a multidis-
ciplinary approach, mainly for treatment
by plastic surgeons, are also referred. To
be successful, a multidisciplinary team
should hold regular and frequent meet-
ings, possess expertise in musculoskeletal
oncological surgery and have the capa-
bility and resources for quick diagnosis
and treatment. The prerequisite for run-
ning an effective multidisciplinary team
is a sufficient number of patients. At the
moment, the STS group of HUCH treats
the majority of STS patients in Finland.
The STS group of HUCH has been
running for almost 17 years now and in
that time it has treated a considerable
number of patients. The same principles
for combining surgery and radiotherapy
as practised at the beginning have been
systematically applied during all these
years. At the same time, experience has
accumulated in operative techniques and
methods of reconstructive surgery. When
introducing new methods of treatment
and diagnostics,  it is essential to assess
the adequacy of older methods to justify
the need, if any, for changes in treatment
programmes. Until a definitive, targeted
treatment against STS at the molecular
level has been developed, the main chal-
lenges in the treatment are how to further
reduce the rate of local recurrence and
need for amputations and to provide
treatment with even better cosmesis and
functional outcome. In these studies, we
evaluate our experience in the treatment
of STS and some other musculoskeletal
malignancies with a view to improving
the management of these diseases in this
country and internationally.
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REVIEW OF THE LITERATURE
mours, skeletal muscle tumours, vascular
tumours, chondro-osseus tumours and
tumours of uncertain differentiation. In
addition, a number of STSs are included
in the WHO’s classifications for neural
tumours, skin tumours and bone tu-
mours (Hogendoorn et al. 2004). A sim-
plified classification of STS by cell type
differentiation is presented in Table 1.
Although STSs are a heterogeneous
group of tumours, they are considered as
one group because of the similarities in
the surgical treatment. Exceptions are
the STSs of children and the sarcomas of
adults located intra- or retroperitoneally,
which are usually treated with different
protocols. The most common histologi-
cal types in adults are malignant fibrous
histiocytoma (MFH) (38%), liposarco-
ma (14%), synovial sarcoma (11%) and
leiomyosarcoma (6%) constituting ap-
proximately 70% of all STSs (Zagars et
al. 2003). In young adults, synovial and
fibrosarcoma are the most common
types, whereas in older persons  MFHs,
liposarcomas and malignant peripheral
nerve sheath tumours (MPNSTs) pre-
dominate. In children, rhabdomyosarco-
ma is the most common STS.
The classification of STS is based on
histology. The most important step
therefore is the examination of haema-
toxylin-eosin-stained sections under
light microscopy at low power. The ar-
chitectural pattern, appearance of the
cells and the characteristics of the stroma
give rise to several differential diagnostic
options. Examination at high power
magnification yields information on the
degree and type of cellular differentia-
tion, mitotic counts and figures, and nu-
clear atypia. More than 70 immunohis-
tochemical markers are commonly
available to help classify tumours accu-
rately. The most important ones are en-
1. Soft tissue sarcomas
1.1 Histology and classification
Soft tissue sarcomas are malignant none-
pithelial soft tissue tumours located ex-
traskeletally. They are generally consid-
ered as primary malignant tumours of
soft tissue. Soft tissue derives from the
mesenchyme, embryological tissue con-
sisting of mesodermal cells that, in the
adult, give rise to  structures such as con-
nective tissues, muscle, blood, lymphat-
ics, bone and cartilage. STSs also include
malignant tumours arising from the pe-
ripheral nervous system because they
present as soft tissue masses and pose
similar problems in diagnosis and treat-
ment (Weiss et Golblum 2001). The cur-
rent thinking is that sarcomas develop
from preprogrammed, undifferentiated,
stem cells originating from tissue pools
or bone marrow and not from mature
cells, e.g. adipocyte or skeletal muscle
cells (Miettinen 2003).
Soft tissue sarcomas constitute a di-
verse group of tumours that are neoplas-
tic and have the propensity to recur lo-
cally or to metastasise distally. They are
classified on the basis of tumour differ-
entiation according to the tissue they re-
semble or are thought to resemble. The
generally accepted basis for soft tissue
tumour classification is the World
Health Organization’s (WHO) classifica-
tion, which was revised in 2002 (Fletcher
et al. 2002). It divides malignant soft tis-
sue tumours or tumours of intermediate
malignancy into more than 60 histologi-
cal types. The main groups are as fol-
lows: adipocytic tumours, fibroblastic /
myofibroblastic tumours, so-called fi-
brohistiocytic tumours, smooth muscle
tumours, pericytic (perivascular) tu-
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dothelial, muscle cell, neural and neu-
roendocrine, melanoma and histiocytic
markers, keratins, other epithelial and
mesothelial markers, other cell type
markers and cell cycle markers. Most im-
munohistochemical markers are not spe-
cific to a certain sarcoma type and the
diagnosis is usually based on the results
of light microscopy and several immu-
nostainings with different markers. In re-
cent times, genetic methods have re-
vealed specific genetic alterations in sev-
eral STS types. These changes are used as
diagnostic tools and they may also be
specific targets for treatment in the fu-
ture (Knuutila et al. 1998, Knuutila et al.
1999, Borden et al. 2003).
Table 1. Main types of STS by cell types they resemble
1.2 Incidence and clinical
presentation
Soft tissue sarcomas are rare tumours. In
Finland, the incidence of STS was 144
new cases in 2002, with an annual inci-
dence rate for females of 1.4 per and for
males of 1.9 per 100 000 person years
(Finnish Cancer Registry 2004). STSs ac-
count for about 1% of all malignancies.
The incidence of benign mesenchymal
tumours is at least 100 times that of
malignant ones. The incidence of STS
increases heavily after 60 years of age.
Approximately 60% of STSs are located
in limbs and, of these, more than two
thirds in the lower limbs. Other sites are
the trunk (17.9%), retroperitoneum
(12.5%), head and neck region (8.9%)
and mediastinum (1.3%) (Lawrence et
al. 1987). On average, 40% of the tu-
mours are located superficially, the re-
mainder being deep-seated (Trovik et al.
2000). One-tenth of the patients have
detectable metastases at diagnosis of the
primary tumour. Of all distant and local
recurrences, 70% develop within two
years and 93% within five years of initial
treatment (Zagars et al. 2003).
Soft tissue sarcoma normally presents
as an enlarging, painless and asympto-
matic soft tissue mass in the limbs or
Type of differentiation Most common sarcoma type
Adipocytic liposarcoma
Fibroblastic / myofibroblastic fibrosarcoma
So-called fibrohistiocytic malignant fibrous histiocytoma
Smooth muscle leiomyosarcoma
Pericytic (perivascular) malignant glomus tumour
Skeletal muscle rhabdomyosarcoma
Vascular angiosarcoma, Kaposi sarcoma
Chondro-osseous extraskeletal chondrosarcoma, extraskeletal 
osteosarcoma
Peripheral nerve MPNST (malignant peripheral nerve sheath
tumour)
Uncertain differentiation synovial sarcoma, epithelioid sarcoma, 
extraskeletal Ewing sarcoma, clear cell sarcoma
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trunk. The consistency varies depending
on the tumour type, but it often resem-
bles a soft, benign lesion such as a lipoma.
In several cases, patients have linked the
occurrence of the tumour with some pre-
vious trauma in the affected area, but
there are no data to support a causal rela-
tionship. Local symptoms usually develop
late (Stefanovski et al. 2002). A large
tumour may cause compression of neural
and vascular structures, resulting in radic-
ular pain, venous stasis and lymphoede-
ma. In the advanced stage, the tumour
may infiltrate the overlying skin, causing
ulceration or necrosis. In a large tumour,
necrosis may cause pain, swelling and
fever (Figure 1). Deep-seated tumours
are often difficult to assess by palpation.
The median tumour size at diagnosis
varies from 6 to 7 cm with a wide range
(Coindre et al. 1996, Vraa et al. 1998).
1.3 Pattern of growth
Soft tissue sarcomas enlarge in a centrif-
ugal fashion. As the tumour grows, pe-
ripheral cells are compressed in parallel
layers, constituting a macro- and micro-
scopic “pushing” border. (Broders et al.
1939) Peripheral to this is the “reactive
zone”, which is composed of granula-
tion-like mesenchymal proliferations
with oedema and neovascularity. Micro-
scopic extensions of the tumour nearly
always pass through the reactive zone
into normal tissue. These two zones have
been called the “pseudocapsule”, as the
gross appearance resembles the anatomic
capsule-like boundary that separates the
tumour from normal-looking tissue.
(Enneking et al. 1981) Skip metastases,
which are tumour tissue but not con-
nected to the parent tumour, are usually
found in high-grade lesions.
1.4 Grading
As well as being divided into histological
types, STSs are graded according to de-
gree of malignancy. The most important
factor predicting the probability of me-
tastases and survival is the histological
malignancy grade (Coindre et al. 1996).
This grade also affects the probability of
local recurrence and has profound influ-
ence on the treatment strategy eventually
chosen. Three grading systems are widely
used. The French Federation of Cancer
Centers (FFCC, also called FNCLCC)
and the National Cancer Institute (NCI)
both use systems with three grades (I
low, II and III high) according to tu-
mour differentiation, mitotic count and
tumour necrosis (Guillou et al. 1997). In
Scandinavia, a four-grade system is gen-
erally used (Markhede et al. 1982, Meis-
Kindblom et al. 1999).  It has indeed
been reported that a four-grade system
(I and II low, III and IV high) increases
the prognostic information (Broders et
al. 1939, Alvegård et al. 1989). All sys-Figure 1. MFH in the forearm
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tems designate tumours as high or low -
grade tumours. Low-grade sarcomas
generally have a good prognosis and a
low capacity for distant metastases,
though local relapses occur after inade-
quate surgical excision. High-grade tu-
mours have a high propensity for distant
metastases and also for local recurrence.
In the four-tiered system, patients with
grade I or II tumours had 100% five-year
survival, grade III 68% and grade IV
47% (Markhede et al. 1982). In the
three-grade system including all loca-
tions, the five-year survival rates for
grades I, II and III tumours were 78.4%,
57.8% and 25.3%, respectively (Hashim-
oto et al. 1992).
1.5 Aetiology
All neoplastic tumours are believed to
arise because of genetic alterations lead-
ing to increased or decreased production
of the proteins, that regulate normal cell
growth and proliferation. In STSs, the ae-
tiology is poorly understood. Only a mi-
nority of STSs can be attributed to known
aetiological agents. Ionizing radiation has
been shown to induce sarcomas in the
previously irradiated field. The most
common types of postirradiation sarco-
mas are MFH and osteosarcoma (Wik-
lund et al. 1991). Postirradiation sarcomas
are usually high-grade tumours. The most
common diseases for which patients re-
ceive radiation therapy are breast, ovarian
and endometrial carcinomas and lym-
phomas. The median latent period from
irradiation to sarcoma diagnosis has been
reported to be 13 years (Amendola et al.
1989). The risk of developing postirradia-
tion sarcoma after radiotherapy with
long-term follow-up has been estimated
to range from 0.03% to 0.80% (Mark et al.
1994). Chronic lymphoedema, either con-
genital or acquired, has been documented
to induce angiosarcomas on rare occa-
sions (Roy et al. 2004). Treatment-related
angiosarcoma occurring in lymphedema-
tous extremity after breast cancer surgery
(Stewart-Treves syndrome) has accounted
for the majority of these cases (Stewart et
Treves 1948).
Oncogenic viruses are responsible for
some sarcoma cases, especially in patients
with immunodeficient conditions such as
AIDS or therapeutic immunosuppression.
There is strong evidence that HHV 8 is
the causative factor in AIDS-associated
Kaposi sarcoma (Chang et al. 1994, Pan-
tanowitz et al. 2004). EBV may also cause
leiomyosarcomas and other smooth-mus-
cle tumours in immunodeficient patients
(McClain et al. 1995).
Exposure to certain toxins has been
proposed to increase the risk of develop-
ing STS. Vinyl chloride, which is a chemi-
cal agent used in the plastics industry, has
been documented to induce hepatic angi-
osarcoma (Evans et al. 1983). An increased
risk of STS in workers exposed to phe-
noxyacetic herbicides and dioxin has also
been reported (Kogevinas et al. 1995). No
increase in risk due to low exposure to di-
oxin via food was detected in a population-
based series (Tuomisto et al. 2004).
A number of genetic diseases predis-
pose to the development of soft tissue tu-
mours and also sarcomas (Zahm et al.
1997). The most important for STS is
type 1 neurofibromatosis (NF 1), in
which patients develop numerous benign
neurofibromas, and in which the risk of
developing malignant peripheral nerve
sheath tumours (MPNST, earlier called
malignant schwannomas) is also in-
creased. Li-Fraumeni syndrome is charac-
terised by familial rhabdomyosarcomas,
early onset of breast carcinoma and other
neoplasms. The inherited form of retino-
blastoma is also associated with the devel-
opment of other malignancies, notably
osteosarcoma. In Gardner’s syndrome, fa-
milial polyposis of the colon occurs with
mesenchymal lesions such as desmoid tu-
mours, aggressive fibromatosis, osteoma
and, infrequently fibrosarcoma.
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1.6 Dermatofibrosarcoma
Dermatofibrosarcoma, also called der-
matofibrosarcoma protuberans (DFSP),
is a low-grade superficial STS originating
in the skin or, rarely, in the subcutaneous
tissue (Diaz-Cascajo et al. 1998). DFSP
typically occurs in young or middle-aged
adults, with male predominance. It com-
prises less than 0.1% of all malignancies
and 1% of STSs (McPeak et al. 1967,
Smola et al. 1991). It is usually located in
the trunk or proximal extremity, but can
occur anywhere in the dermis (Figure 2).
DFSP behaves like low-grade superficial
STS and tends to grow slowly.
Histologically, DFSP is a mesenchy-
mal tumour originating in the dermis
and consisting of fusiform fibroblasts ar-
ranged in a cartwheel or storiform pat-
tern. It is distinguished from fibrosarco-
ma by features such as absence of
nuclear atypia, increased mitotic rate
and increased cellularity. DFSP is posi-
tive for the immunohistochemical mark-
ers vimentin and CD 34. The origin of
DFSP is indeed attributed to periadnexal
cd 34-positive fibroblasts as their immu-
nohistochemical profile is similar to that
of DFSP. Immunohistochemical staining
for CD 34 is especially helpful in differ-
ential diagnosis of DFSP and dermatofi-
broma (also called benign fibrous histio-
cytoma, BFH, histiocytoma). Recently, a
novel immunohistochemical marker,
apolipoprotein D, which is relatively spe-
cific for DFSP, has also been reported to
be useful in differential diagnosis of
DFSP and dermatofibroma (West et al.
2004). Ring chromosomes containing
material from chromosomes 17 and 22
are typical cytogenetic changes in DFSP
in adults (Naeem et al. 1995). DFSP has a
specific t(17;22)(q22;q13) translocation
with COL1A – PDGFB gene fusion (Si-
mon et al. 1997), resulting in production
of platelet-derived growth factor beta
(PDGF β), subsequently leading to auto-
crine growth stimulation of the tumour.
Histological tumour margins usually
extend far beyond the gross margins,
with tentacle-like projections. DFSP typ-
ically recurs locally unless complete exci-
sion is performed. Local recurrences
tend to develop late, 25–30% of them
more than five years after the initial
treatment (Snow et al. 2004, Chang et al.
2004). Metastasis is rare and occurs in
fewer than 4% of patients; it is common-
ly preceded by multiple local recurrenc-
es. Metastases tend to develop in DFSPs
with fibrosarcomatous changes, but are
not necessarily preceded by de-differen-
tiation in local recurrence (Rutgers et al.
1992, Mentzel et al. 1998).
Figure 2. Dermatofibrosarcoma in the epigastrium
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1.7 DNA copy number changes in
recurrent tumours
In general, the evolution of a malignant
tumour is initiated at the molecular
level. In some tumours these initial
changes lead to alterations in the DNA
sequence copy number, where single
genes may have been multiplied or lost
(Struski et al. 2002). At the chromosom-
al level, these changes in DNA copy
number may be visible as losses or gains
of particular chromosomal regions or
even of entire chromosomes. Compara-
tive genomic hybridisation (CGH) de-
tects alterations in the DNA sequence
copy number, in other words, gains, loss-
es and high level amplifications, screen-
ing the whole tumour genome in a single
hybridisation (Kallioniemi et al. 1992).
The alterations detected can be used as
differential diagnostic tools, prognostic
markers or markers predicting a re-
sponse to targeted treatment (Hogen-
doorn et al. 2004). Comparisons between
a primary tumour and its recurrence of-
fer a longitudinal view of tumour pro-
gression.
At present, little is known about the
local genetic progression of STS. Only a
few reports about cytogenetic changes in
primary and locally recurrent STS ap-
pear to have been published (Örndal et
al. 1993, Mandahl et al. 1989). In one of
these, the evolution of a fibrosarcoma
was monitored by cytogenetic methods
over a period of 26 months, revealing
that choromosomal aberrations in-
creased in parallel with clinical and his-
topathological tumour progression
(Örndal et al. 1993). An increase in copy
number aberrations in local recurrences
studied by CGH has also been found in
in situ ductal breast carcinomas (Wald-
man et al. 2000) and in prostate cancer
(Visakorpi et al. 1995). No large series
concerning genetic changes in primary
and locally recurrent STS studied by
CGH have been reported.
Genetic tumour progression has
been more extensively studied in meta-
static disease. An increase in the total
number of changes during tumour pro-
gression has been found between prima-
ry sarcomas and their pulmonary metas-
tases (Tarkkanen et al. 1999). An increase
in copy number aberrations from a pri-
mary tumour to a metastasis, studied by
CGH has also been detected in breast
cancer (Nishizaki et al. 1997), melanoma
(Balázs et al. 2001), colorectal cancer
(Al-Mulla et al. 1999, Jiang et al. 2005),
aesthesioneuroblastoma (Bockmühl et al
2004) and fibrolamellar hepatocellular
carcinoma (Wilkens et al. 2000).
Specific alterations for metastatic tu-
mours have not been detected in sarco-
mas (Tarkkanen et al. 1999), breast can-
cer (Nishizaki et al. 1997) or small-cell
lung carcinoma (Schwendel et al. 1997).
In renal clear cell carcinoma, an increase
in the copy number of genes located at
1q has been reported to correlate with
metastatic events (Gronwald et al. 1997).
In colorectal cancer, loss of 4q has been
suggested as a potential supplementary
factor for dissemination of the disease
(Jiang et al. 2005). In aesthesioneurob-
lastomas, deletions on chromosome 11
and gains of 1p are associated with me-
tastasis formation and poorer prognosis
(Bockmühl et al. 2004).
2. Treatment of soft tissue sar-
comas of the extremities
2.1 Diagnosis
Biopsy is the critical step in the diagnosis
of soft tissue tumours. The methods com-
monly available are open surgical biopsy,
core-needle biopsy (CNB) and fine needle
aspiration (FNA). Surgical biopsy takes
the form of either incisional biopsy, in
which wedge-shaped sample of tumour is
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incised, or excisional biopsy, in which the
entire macroscopic tumour is removed. In
the past, before treatment was sentralised,
open biopsies were favoured. Surgical bi-
opsy is, however, an inherently difficult
procedure, with high potential to spread
the disease and jeopardise limb-salvage
treatment. In a series of patients that in-
cluded biopsies performed in referring in-
stitutions and those performed at the
treatment centre, the rate of diagnostic er-
ror for open biopsies was as high as 18%,
and problems with the biopsy forced the
surgeon to carry out a different, and often
more complex, operation or to use ad-
junctive RT or chemotherapy in 19% of
patients (Mankin et al. 1996). For this rea-
son and due to the development of other
methods, surgical biopsies have nowadays
been mainly replaced by CNB and FNA.
In the infrequent cases in which surgical
biopsy is required, it should be performed
by the definitive operating surgeon, so
that it is planned in concordance with the
eventual operation. It has been proposed
that superficial soft tissue tumours larger
than 5 cm and all deep seated lesions
(with a 10 % risk of malignancy) should
be referred to a specialised centre before
any surgical procedures are conducted
(Rydholm 1983).
Needle biopsies are minimally inva-
sive procedures and they have mostly re-
placed surgical biopsies. CNB has been
shown to have a sensitivity of 82–100%
and a specifity of 91–100% in STS, with
complication rates of 0–1.1% (Welker et
al. 2000). CNB is as effective as incisional
biopsy in the diagnosis of soft tissue tu-
mours and the subtyping or grading of
STS and has, moreover, lower morbidity
(Hoeber et al. 2001). CNB and FNA can
also be combined to increase accuracy.
FNA provides only a cytological sample
with scant tissue, and thus exact typing
and grading are not usually possible.
However, in the diagnosis of sarcoma, a
positive predictive value of 99% has been
reported when the cytopathologist was
provided with clinical information
(Thunnissen et al. 1993). In tumours
with a hard consistency yielding a non-
diagnostic CNB, FNA may be diagnostic
as it penetrates the tumour more readily
than CNB. To ensure representative sam-
ples at the first attempt, needle biopsies
are usually taken under ultrasound or
computed tomography (CT) guidance.
Guidance with radiological methods is
particularly important in deep tumours
and in tumours containing radiologically
divergent areas.
2.2 Surgical margin
Surgery is the first-line treatment in the
management of STS. Owing to infiltra-
tive growing, plain macroscopic tumour
removal, the “shelling-out procedure”,
results in local recurrences in a majority
of cases. Until the 1970’s, amputation
was the only curative option for patients
with STS. At many centres, sarcomas
were first locally excised, usually with in-
adequate margins. Then, if the tumour
recurred locally, the limb was amputated.
This resulted in amputations in nearly
half of the patients (Shiu et al. 1975).
In 1981, Enneking evaluated the im-
portance of fascial boundaries to local
recurrence rate (Enneking et al. 1981). In
a classification that forms the basis for
the concept of surgical margin in sarco-
ma surgery, he divided the surgical mar-
gin into four types: in the intralesional
margin, the tumour forms the periphery
of part or all of the specimen; in the
marginal margin, a pseudocapsule forms
the periphery of the specimen; in the
wide margin, a cuff of non-reactive nor-
mal tissue forms the periphery of the
specimen; and in the radical margin, all
normal tissue of the compartment(s) in-
volved encases the specimen en bloc. Be-
cause, theoretically, sarcomas do not
penetrate fascial boundaries, the radical
margin leaves no residual microscopic
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disease. Enneking applied his classifica-
tion of margin to both excisions and am-
putations. However, in clinical practice,
the term “radical margin” or “radical sur-
gery” should be addressed with caution,
since it has been used to describe mar-
gins that are maximal in the surgeon’s
judgement, without any connection to
the actual histological margin.
Enneking’s classification has been
accepted worldwide. Nevertheless, it is
not always sufficiently accurate due to
the broad range of definitions of wide
surgical margin. According to Enneking’s
definition, a margin is wide when it is
surrounded by a cuff of normal tissue ir-
respective of its thickness (Enneking et
al. 1981). In recent years, though, a vari-
ety of more accurate descriptions of the
surgical margin have been used. Com-
mon practice is to classify margins as
positive or negative. A positive margin
has been defined as one in which tu-
mour cells are present at or within 1 mm
of the resection margin, but which is
otherwise negative (Alektiar et al. 2002).
In some reports, margins have been doc-
umented as grossly positive, microscopi-
cally positive, close (5 mm or smaller) or
negative (Herbert et al. 1993); in others
as clear (>10 mm), close (1–9 mm) or
positive (McKee et al. 2004).
Radiotherapy combined with sur-
gery has been shown to reduce local re-
currences (Rosenberg et al. 1982, Pisters
et al. 1996, Yang et al. 1998). Implying
that RT eliminates viable tumour cells
left in the operation area, this finding has
resulted in narrower margins and less
mutilating operations. Radical or com-
partmental margins cause abundant
morbidity, and they are no longer goal of
treatment. However, even with RT, the
rate of local recurrence is increased
when postoperative margins are positive
(Herbert et al. 1993, Sadoski et al. 1993,
Alektiar et al. 2002). Thus, optimal surgi-
cal removal of the disease is still of para-
mount importance.
The only prognostic factor the sur-
geon can influence is the surgical mar-
gin. A positive microscopic surgical mar-
gin is an unfavourable prognostic factor
for local control and disease-free survival
(McKee et al. 2004, Vraa et al. 1998). The
extent of the adequate surgical margin
has not, however, been uniformly de-
fined. Moreover, few studies have been
conducted on the link between a precise
margin width and outcome.
Wide excision is usually considered
to be resection of the tumour with a rim
of normal tissue in the judgement of the
surgeon, regardless of the thickness of
the normal tissue rim (McKee et al.
2004). In a recent report from the
Roswell Park Cancer Institute, in ap-
proximately one half of the tumours
treated with wide excisions, the closest
margin of resection measured less than 1
cm, and in 10% of the widely excised tu-
mours microscopic margins were posi-
tive (McKee et al. 2004). Similar results
have been published earlier (Pisters et al.
1996, Sadoski et al. 1993, Lewis et al.
2000). The prognostic factor for local re-
currence was a margin width less than
1 cm, and in these cases postoperative
radiotherapy is recommended (McKee
et al. 2004). In an 837 patient-series from
Tokyo, the largest reported to date, the
width of surgical margins was analysed
in detail. Margins greater than 2 cm re-
sulted in approximately 90% local con-
trol (p<0.001)  (Kawaguchi et al. 2004).
The system of margin evaluation used in
the study, drafted by the Bone and Soft
Tissue Committee of the Japanese Or-
thopaedic Association in 1989, is the
most comprehensive published and can
be applied to bone sarcomas. It also takes
into account the role of barriers (the tis-
sues resisting tumour invasion e.g. fascia,
joint capsule, tendon). The authors con-
clude that, for high-grade sarcomas, the
margin should be wider than 3 cm; for
narrower margins, RT is recommended
(Kawaguchi et al. 2004).
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2.3 Radiotherapy
Progress in RT has made more conserva-
tive surgery possible. The efficacy of RT
combined with surgery has been well
documented to improve local control in
the STS of the extremities (Rosenberg et
al. 1982, Pisters et al. 1996, Yang et al.
1998). The use of RT has enabled the size
of resection margins to be reduced to
wide or even marginal. Radical resection
margins, which are most often feasible
only by amputation, are nowadays sel-
dom encountered.
Radiotherapy can be applied exter-
nally either before (preoperative) or after
(postoperative) the surgery. In brachy-
therapy, the radiation dose is delivered at
a low rate for a few days after surgery
through catheters placed in the surgical
bed during the operation (Alektiar et al.
2002). In intraoperative RT, the radiation
dose is delivered during the surgery ei-
ther through high dose rate radioactive
catheters in the surgical bed (Kretzler et
al. 2004) or via an electron beam acceler-
ator fitted in the operating room (Lehn-
ert et al. 2000 ). In a randomised trial,
intraoperative RT combined with post-
operative RT reduced local recurrences
of retroperitoneal sarcomas as compared
with postoperative RT alone (Sindelar et
al. 1993). In all RT, irrespective of the
specific technique used, it is essential to
avoid radiation of joints or full limb cir-
cumference. It has also been reported
that the risk of radiation-induced femo-
ral shaft fracture is 29%, when radiation
is combined with periosteal stripping
(Lin et al. 1998).
External beam RT is the most widely
used modality, since practices for its use
are routine nowadays, and  its application
is technically less complex. In a ran-
domised prospective study, it was report-
ed that, in local control, conservative sur-
gery with external beam RT is as effective
as amputation in high-grade STS (Rosen-
berg et al. 1982). Another randomised
prospective trial found that external beam
RT improves local control for both high
and low-grade tumours in extremities
(Yang et al. 1998). RT is more commonly
given postoperatively than preoperatively.
Postoperative RT has the following ad-
vantages: the operation can be performed
without delay; the surgical specimen and
margins can be accurately histologically
analysed; and, in the event of wide mar-
gins, RT can be omitted. Nevertheless, pr-
eoperative RT may be favoured in efforts
to reduce the tumour size before surgery
with a view to minimising the resection
area, reducing the seeding of viable tu-
mour cells over the operative field and re-
ducing the treatment volume. However, a
randomised trial comparing pre- and
postoperative RT, with wound complica-
tions as an end point, found that preoper-
ative RT was associated with a greater risk
of wound complications (O’Sullivan et al.
2002). In another randomised trial, the
delivery of RT either pre- or postopera-
tively had only minimal impact on the
function of patients (Davis et al. 2002).
Preoperative RT and chemotherapy also
cause tumour necrosis and thus confound
histopathological typing and grading of
the surgical specimen. Neither sequencing
of RT with surgery has been proved to
provide a reliable benefit for outcome
(Strander et al. 2003). Preoperative RT is
recommended for large tumours in a dif-
ficult location to reduce their size and to
make conservative surgery possible (Rob-
inson et al. 1998).
In one randomised trial, brachyther-
apy reduced the number of local recur-
rences in high-grade tumours (Pisters et al.
1996), whereas in another the reopera-
tion frequency due to wound complica-
tions was higher with brachytherapy and
surgery than with surgery alone, but
lacked statistical significance (Alektiar et
al. 2000). In general, local control rates
and complications are similar to those of
external beam RT, and the choice of RT
method depends on the institution, the
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physician’s expertise and the clinical sit-
uation (Strander et al. 2003). Some au-
thors have even concluded that RT
should be applied to low-grade tumours
under the same principles as for high-
grade tumours (Choong et al. 2001, Yang
et al. 1998).
Current treatment protocols com-
bine a wide variety of surgical proce-
dures with some modality of RT. An im-
portant distinction in the pattern of
multimodality therapy is whether RT is
combined with surgery routinely or se-
lectively. In most series, RT is delivered
liberally to nearly all patients with varia-
ble widths of postoperative excision mar-
gins (Zagars et al. 2003). In a report from
Italy, RT is delivered to all high-grade tu-
mours and to marginal resections in tu-
mours of any grade (Stefanovski et al.
2002). Current treatment protocols rec-
ommend radiation therapy for all tu-
mours greater than 5 cm (Pisters et al.
1998, Demetri et al. 1998). The non-se-
lective application of postoperative RT to
all, at least to high-grade, sarcomas is
probably due to the lack of recommen-
dations for safe margins. A selective
combination of treatment modalities, in
which the delivery of RT is based on
depth and surgical margins, has been
employed in some countries, e.g. in
Scandinavia (Trovik et al. 2001) and Ja-
pan (Kawaguchi et al. 2004).
2.4 Adjuvant chemotherapy
According to meta-analysis of 14 ran-
domised trials comprising a total of 1568
patients, doxorubicin-based adjuvant
chemotherapy appeared to significantly
increase the time to local or distant re-
currence and to improve the overall re-
currence-free survival rate in adults with
localised resectable STS. Significant ab-
solute benefits were 6-10% at 10 years,
and there was some evidence of a trend
towards improved overall survival (Sar-
coma Meta-Analysis Collaboration,
2000). A recent randomised trial also
found that the impact of chemotherapy
was significant for disease-free survival
and overall survival (Frustaci et al. 2001),
although contradictory results have been
reported, too (Gortzak et al. 2001).
2.5 Centralisation of treatment to
multidisciplinary teams
A multidisciplinary approach consisting
of conservative surgery, modern recon-
structive methods and RT has proved to
be the most effective method in local con-
trol and in efforts to preserve a functional
limb (Wiklund et al. 1996, Gustafson et al.
1994). In a large SSG study based on 1851
patients treated in 1986-1997 , a wide or
compartmental margin was achieved in
66% of patients operated on at sarcoma
centres as compared to 11% of those op-
erated on elsewhere, with five-year local
recurrence free survival rates of 80% and
30%, respectively (Bauer et al. 2001). In
another series from Sweden, this one with
375 patients, the local control rate for pa-
tients referred to a specialist centre before
surgery was 82%, for those referred after
surgery 76%  and for those not referred at
all 55% (Gustafson et al. 1994). In a re-
port from the USA, 91% of the patients
referred to a specialist centre after an exci-
sion judged to be complete in a local hos-
pital were found to have microscopic re-
sidual tumour in the wider re-excision
specimen (Karakousis et al. 1995). In a re-
gional audit from the UK evaluating STS
treatment practice in 1986-1992, 21% of
patients satisfied the criteria for optimal
preoperative investigation, 40% did not
have any cytological or histological confir-
mation of the diagnosis before supposed
definitive surgery, and only 60 % were
eventually treated adequately (Clasby et
al. 1997). In a recent series from France,
only 7% of patients were reviewed by a
multidisciplinary team before biopsy, and
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clinical practice guidelines for initial sur-
gery were fulfilled in 52% of patients
(Ray-Coquard et al. 2004). In a historical,
population-based study from Finland, the
local control rate for patients with ex-
tremity STS was 57%, with an amputa-
tion rate of 10% (Rantakokko et al. 1979).
In a more selected series from our hospi-
tal before the multidisciplinary treatment
era, the three-year disease-free survival
rate was 36% (Gröhn et al. 1979) whereas
in the preliminary report on the present
series the three-year disease-free survival
rate was 69% (Wiklund et al. 1996). In
the light of the better conformity in diag-
nostics and the more favourable treat-
ment results, centralisation of the treat-
ment of STS is recommended.
2.6 Treatment protocol at Helsinki
University Central Hospital
The HUCH treatment protocol includes
all adult STSs excluding visceral sarcomas,
DFSP and Kaposi sarcoma. The principles
of treatment are surgery selectively com-
bined with postoperative RT. A detailed
description of the extent of surgical mar-
gins and the combination of surgery with
RT is given in the section Materials and
Methods. Preoperative RT is delivered to
large tumours in difficult locations where
even marginal surgery does not seem fea-
sible and conservative surgery is attempt-
ed. RT is planned by means of CT scan-
ning. The target volume is the involved
muscle compartment in a transversal di-
rection, and a margin of at least 5 cm lon-
gitudinally. Whenever possible, a strip of
subcutaneous tissue, long bone or joint is
spared. In both preoperative and postop-
erative RT, the radiation dose is 50 Gy
over a period of five weeks. A boost of 10-
20 Gy is delivered at a smaller target vol-
ume to microscopically positive surgical
margins.
At present, adjuvant chemotherapy
is given to all patients under 70 years of
age with high-grade tumours or tu-
mours that fulfil two of the following
criteria: size larger than 8 cm (in synovi-
al sarcomas 5 cm), necrosis, vascular in-
vasion. Adjuvant chemotherapy is also
considered for patients in whom surgery
and RT are not expected to give adequate
local control. Adjuvant chemotherapy
consists of an adriamycin-ifosfamid
combination that is given six times with
three-week breaks between treatments.
Chemotherapy is applied with a different
scheme to histological types such as ex-
traskeletal Ewing sarcoma, PNET, ex-
traskeletal chondrosarcoma, extraskeletal
osteosarcoma, rhabdomyosarcoma, ma-
lignant mesenchymoma, clear cell sarco-
ma, alveolar soft part sarcoma and epi-
thelioid sarcoma.
Currently, all patients with pulmo-
nary metastases undergo metastasectomy,
if feasible. After surgery, chemotherapy is
delivered to patients under 70 years of age
if the number of metastases exceeds five
or disease-free survival is expected to be
less than six months. Inoperable metas-
tases are treated with chemotherapy.
The follow-up interval for high-
grade tumours is two months during the
first two years and thereafter four
months, and for low-grade sarcomas
four and six months, respectively. A chest
x-ray is taken at each follow-up visit and
also a chest CT when necessary. A CT or
MRI scan from the operative area is rou-
tinely taken six months postoperatively
in high-grade sarcomas and one year
postoperatively in low-grade STS, and
thereafter if local recurrence is suspect-
ed. Patients are routinely followed for at
least five years.
2.7 Surgery for locally recurrent
disease
Local recurrence presents a challenge in
the treatment of STS. The frequency of
local recurrence ranges from 10% to
22
60%, depending on the extent of the sur-
gery performed. Today, the rate of local
recurrence is considered as an indicator
of the quality of primary treatment.
However, it is well known that patients
with local recurrence are more prone to
develop distant metastases (Lewis et al.
1997). Consensus is lacking as to wheth-
er this is a sign of a more malignant tu-
mour with a greater propensity to spread
or whether there is a causal association
between local recurrence and the devel-
opment of distant metastases. Prior local
recurrence was reported as a significant
factor for subsequent local recurrences
in the largest series published (Pisters et
al. 1996, Zagars et al. 2003).
With modern treatment for primary
tumours, the frequency of local recur-
rences reported in most series has been
10-20% (Table 3). In a study on patterns
of recurrence, the disease recurred in 35%
of patients, with isolated local recurrences
accounting for about 20% and local re-
currences with synchronous metastases
for 4% of all disease recurrences (Potter et
al. 1985). Thus the frequency of patients
presenting with an isolated local recur-
rence after multidisciplinary treatment
was no more than 7%. The outcome may
be more favourable for late recurrences,
since 50% of recurrences occurring later
than five years after initial treatment were
local failures alone as compared with 25%
of the recurrences occurring earlier than
five years after initial treatment (Gibbs et
al. 2000). Previous surgery and / or RT for
primary tumour make the operating con-
ditions more difficult. It is thus also more
difficult to achieve adequate local control
(Robinson et al. 1990). In isolated local
recurrences treated surgically, the five-
year local recurrence-free and overall sur-
vival rates were 72% and 77%, respective-
ly, with an amputation rate of 25% (Midis
et al. 1998). In another series, the amputa-
tion rate was 22%, which was more than
twice as high as with primary tumours
(Trovik et al. 2000). Aggressive surgical
treatment of local recurrences would
seem to be justified in the light of relative-
ly good results achieved after adequate
treatment of local recurrence.
2.8 Isolated limb perfusion and
other neoadjuvant treatments
Isolated limb perfusion (ILP) is a treat-
ment method, in which the limb is isolat-
ed from the systemic circulation and per-
fused with anti-tumour drugs. ILP
exposes tumours to drug concentrations
20 times as high as in systemic therapy
(Benckhuijsen et al. 1988). Although ILP
was initially described in 1958 (Creech et
al. 1958), it has mainly been employed
during the last 15 years, most frequently
in melanoma and STS. There are no stud-
ies on ILP in locally resectable STS (Noor-
da et al. 2004). No randomised trials have
been conducted on ILP in unresectable
STS, though several retrospective series
have been reported. The treatment proto-
col most often described is mild hyper-
thermic perfusion with melphalan and
TNF-α, in some patients with additional
IFN-γ (Eggermont et al. 1996). In the
largest series, comprising 186 patients
treated with ILP combined with surgery,
64% of patients attained local tumour
control with limb preservation (Egger-
mont et al. 1996). Limb salvage rates from
57% to 86% have been reported in small-
er series (Noorda et al. 2003, Lejeune et al.
2000). Another method of treatment for
locally advanced tumours is intra-arterial
chemotherapy combined with preopera-
tive RT, but this has been associated with
a high rate of complications and toxicity
(Huth et al. 1988). According to a recent
meta-analysis consisting of 19 series with
a total of 1173 patients, ILP seems to be a
more effective limb sparing, neoadjuvant
treatment modality than any of the other
neoadjuvant treatment options for unre-
sectable STS of the limb (Noorda et al.
2004).
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2.9 Surgery for metastatic disease
Pulmonary metastases affect from 20%
to 38% of all STS patients (Potter et al.
1985, Gadd et al. 1993, Billingsley et al.
1999). The most common site for metas-
tases is the lungs, and most patients dy-
ing from STS have pulmonary metastas-
es. Pulmonary metastases without
synchronous recurrence at other sites is
the most common pattern of recurrence
and accounts for about half of all disease
recurrences (Potter et al. 1985). There
are no prospective randomised studies
on the impact of resection of pulmonary
metastases on survival. In a meta-analy-
sis of 2612 patients, resection of pulmo-
nary metastases yielded five-year survival
rates of 21–38%, with median survival of
18–21 months (Chao et al. 2000). For a
few  patients, the procedure may even be
curative (Gadd et al. 1993, Casson et al.
1992). These clinical series suggest that
metastasectomy improves survival.
Moreover, in a recent study of 1124 pa-
tients with pulmonary metastases, pul-
monary resection was the most cost-ef-
fective treatment strategy (Porter et al.
2004). Multiple studies have shown that
the most important favourable predictor
for survival is the ability to completely
resect all disease (Van Geel et al. 1996,
Pastorino et al. 1997, Billingsley et al.
1999, Verazin et al. 1992). Negative
markers for survival in most studies have
been rapid tumour doubling time (less
than 20 days), short disease-free interval
(less than 12 months) and high tumour
grade. A new method for the treatment
of pulmonary metastases is isolated lung
perfusion with chemotherapeutic agents.
The clinical value and survival benefit of
this new treatment are being tested in
ongoing trials (Van Putte et al. 2003).
In most types of STS, metastases of
the lymph nodes are relatively  rare. Ex-
ceptions are rhabdomyosarcoma, epithe-
lioid, clear cell, synovial and vascular sar-
comas (Blazer et al. 2003). In a recent
series of 1066 patients, 39 (3.6%) devel-
oped lymph node metastases. Resection
of the lymph nodes involved led to five-
year survival of 57%, whereas patients
treated without surgery all died within
30 months (Riad et al. 2004). In an earli-
er series of 1772 patients, radical lym-
phadenectomy for patients with nodal
involvement in the absence of other me-
tastases yielded 34% five-year survival
(Fong et al. 1993). These results suggest
that aggressive surgical treatment for
lymph node metastases is justified.
Sentinel node biopsy (SNB) is not
currently a routine procedure in the treat-
ment of STS, since sarcomas do not usu-
ally send metastases to regional lymph
nodes. Its use has been reported only in
the sarcomas with a propensity for lymph
node metastasis, e.g. clear cell sarcomas
(Al-Refaie et al. 2004) and childhood
rhabdomyosarcomas (McMulkin et al.
2003). The value of SNB is currently be-
ing investigated in these tumours, but due
to the rarity of these diseases no patient
series has as yet been reported.
2.10 Reconstructive surgery in limb
salvage
Wide or even marginal excision of STS
often causes a large soft tissue defect, and
the wound cannot then be closed due to
a lack of soft tissue. In cases of direct
wound closure, the excessive tension in
the wound edges reduces the blood flow
in the wound, thus impairing the capaci-
ty for healing. In a randomised study on
the complications of brachytherapy, a
width of excised skin exceeding 4 cm re-
sulted in a significantly higher re-opera-
tion rate (Alektiar et al. 2000). If the
floor of the operative field contains mus-
cle, skin grafts may be used for recon-
struction. However, if tendons, joints,
major vessels or nerves are exposed, the
reconstruction has to be performed with
vascularised tissue. Immediate vascular-
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ised tissue transfers are particularly im-
portant in defects of the thoracic and ab-
dominal walls or cranium, where the
lack of soft tissue would otherwise leave
vital organs exposed.
Traditionally, two types of flap have
been available for reconstruction, local
and pedicled. These flaps may contain
skin and subcutaneous tissue and / or
muscle. Pedicled flaps are connected to
the circulation via their vascular pedicle
and local flaps via their base, which con-
sists of skin and subcutaneous tissue. The
flaps are transposed or rotated to their
new location to cover the defect. Howev-
er, the arch of rotation limits the use of
such flaps and they do not always extend
far enough to cover the defect. Moreover,
flaps may already have been used, they
may have been violated by previous sur-
gery or RT, or their elevation might cause
unacceptable morbidity to an already
compromised extremity. Further, in cases
where the extent of the tumour excision is
inadequate, harvesting a local flap may
spread the disease to the donor site.
Progress in microvascular techniques
has solved many of the problems associ-
ated with local or pedicled flaps, so
much so that free flaps are now everyday
workhorse techniques with high success
rates. In a series of 854 free flaps from
the MD Anderson Cancer Center, the
overall success rate was 96% (Kroll et al.
1996), and a report from the Memorial
Sloan-Kettering Cancer Center on recon-
struction for oncological defects in 716
free flaps gives an overall success rate of
98%, with an 8% re-exploration rate.
Only five flap types were necessary to
solve most problems in the extremities.
The flap most commonly used in the
lower limb was the latissimus dorsi
(53%) followed by the rectus abdominis
muscle and the fibula. In the upper limb,
the fibular flap (52%) was the most
common followed by the rectus ab-
dominis muscle and the latissimus dorsi
(Hidalgo et al. 1998). The success rate for
free flaps in oncological surgery is simi-
lar to that in other free flap applications
(Cordeiro et al. 1994).
It is generally agreed that RT inter-
feres with wound healing. A significant
increase in skin-graft loss after external
beam RT, despite a good initial graft up-
take, was detected in an experiment with
rats (Tadjalli et al. 1999). Partial or total
skin-graft loss after RT has been reported
in 10% of oncological patients. It is nev-
ertheless concluded that their use is rela-
tively safe if they are placed on well-vas-
cularised muscle beds (Bui et al. 2004).
External beam RT did not affect the sur-
vival of free flaps in rats (Virolainen et
al. 2002). In a series of 43 patients with
free flaps, pedicled flaps and skin grafts,
tissue transfers tolerated postoperative
external beam RT well, but brachythera-
py was followed by an increase in wound
complications (Spierer et al. 2003). In a
series of 100 fibular free flaps, complica-
tion rates in patients receiving external
beam RT were no higher than in patients
not receiving RT (Choi et al. 2004). A
free flap or regional flap permits radia-
tion of the tumour site and can safely be
used in oncological surgery when RT is
required (Evans et al. 1997, Hidalgo et al.
1998, Lee et al. 2004).
The results for free tissue transfer to
a previously irradiated site vary. Prior ir-
radiation makes dissection of recipient
vessels more difficult and may interfere
with the development of collateral circu-
lation from surrounding tissue to the
flap. In a multivariate analysis of 1384
free flaps used for breast and head and
neck reconstruction, previous irradiation
of the operative field did not affect free
flap success (Kroll et al. 1998). It was,
however, a significant factor in flap fail-
ure in a prospective multivariate analysis
of 493 free flaps, with a failure rate of 9%
(Khouri et al. 1998). It is therefore advis-
able to be prudent in irradiated areas and
to ensure that only reliable flaps are
used.
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Reconstructions with free tissue
transfers have been shown to have many
advantages over direct wound closure.
Tumours can be operated on with wider
margins (Lohman et al. 2002), and even
muscle function can be restored if neces-
sary (Doi et al. 1999). In addition to skin,
subcutaneous tissue and fascia, the free
flap may contain muscle and vascular-
ised bone tissue. The flap type and its
composition are selected to closely suit
the anatomy of the defect and to fulfil
functional demands. Nowadays, primary
amputation is usually only performed if
the tumour infiltrates major neurovas-
cular structures; even in some of these
cases, it has been recommended that the
limb should be salvaged with the aid of
vascular reconstructions (Hohenberger
et al. 1999). Modern plastic surgical
methods, such as the use of muscle and
musculocutaneous free flaps and pedi-
cled flaps, allow immediate reconstruc-
tion and should be available when need-
ed in STS and other oncological surgery
(Reece et al. 1994, Anthony et al. 1993).
2.11 Extensive amputations and
specific techniques
Although salvage of the limb is the aim
of treatment, amputations cannot always
be avoided in STS surgery. If the sacrifice
of major nerves or considerable shorten-
ing of the lower extremity would lead to
poor function, amputation may be a
preferable option. Extensive amputations
are sometimes required in proximal ex-
tremities, and in thoracic and pelvic gir-
dle regions if the tumour infiltrates the
neurovascular bundle. These procedures
include forequarter amputation, extend-
ed forequarter amputation and external
hemipelvectomy. Such operations are re-
garded as among the most mutilating
procedures in cancer treatment. The
prognosis for patients tends to be poor
due to recurrence, large size and high
grade of the tumour. However, in select-
ed patients these procedures may be cur-
ative and in others palliative, relieving
symptoms such as pain, fetor, bleeding,
persistent infection and discharge. In a
40-patient series consisting of all the ex-
tensive amputations for STS performed
at one institution, the two-year disease-
free survival rate was 23% (Clark et al.
2003). In another series of patients who
underwent a curative operation, the five-
year survival rate after forequarter am-
putation was 30% (Bhagia et al. 1997).
These procedures are infrequent and re-
quire considerable expertise in recon-
struction.
In procedures such as external hemi-
pelvectomy and extended forequarter
amputation, coverage of the defect may
require a free flap. Free flaps dissected
from the amputated upper extremity
(fillet flap) have been used, the advan-
tages being a lack of donor site morbidi-
ty (Cordeiro et al. 1998) and the feasibil-
ity of reconstructing the shoulder
contour (Osanai et al. 2005). In hemipel-
vectomy, the vascularity of local skin
flaps is often compromised by resection,
and flap necrosis has been the most
common complication reported in 38%
of patients (Baliski et al. 2004). The
pedicled vertical rectus abdominis myo-
cutaneous (VRAM), tensor fascia latae
(TFL) and rectus abdominis muscle flaps
(Ross et al. 1998) as well as fillet flaps
from the amputated lower extremity
have been used to cover large defects
caused by hemipelvectomies. Fillet flaps
can be raised both as free flaps (Tran et
al. 2000) and as pedicled flaps (Butler
2002) with good results.
Certain methods of resection are
preferable to amputation in terms of
body contour and function. Tikhoff-Lin-
berg humeroscapular resection is superi-
or to forequarter amputation in tumours
of the shoulder, proximal humerus and
scapula, assuming that the axillary neu-
rovascular pedicle is tumour free
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(Voggenreiter et al. 1999). Recently, en-
doprosthetic scapular reconstruction has
shown some promising results in shoul-
der movement as compared with plain
resection (Wodajo et al. 2003). In tu-
mours of the upper arm, segmental am-
putation of the involved region and re-
plantation of the lower arm to the
proximal humerus gives better function-
al results than amputation (Windhager
et al. 1995).
In distal amputations specific recon-
structions are sometimes needed. In a
non-conservatively  treatable  tumour in
the leg, where the excision of soft tissues
would not allow bone coverage and
would thus lead to above-knee amputa-
tion, the amputation level can be made
more distal by free flap coverage and / or
bone elongation, giving a better func-
tional result. Experience in covering am-
putation stumps with free flaps has been
accumulated mostly through trauma
surgery, and some surgeons consider the
fillet of foot free flap as a first choice
(Kasabian et al. 1995). A classical meth-
od used mainly in children to preserve
the important function of the knee joint
is rotationplasty of the leg, in which a tu-
mour involving the knee joint is resected
with the joint, and the ankle joint is ro-
tated 180 degrees and joined to the fe-
mur (Van Nes 1950, Fuchs et al. 2004).
2.12 Tumour- and patient-related
clinical prognostic factors for local
recurrence
In the literature, the prognostic factors
for distant metastasis and local recur-
rence in STS differ (Zagars et al. 2003).
Most studies give tumour grade, tumour
size and tumour depth related to invest-
ing fascia as important factors for distant
metastasis (Pisters et al. 1996, Ste-
fanovski et al. 2002, Coindre et al. 1996,
LeVay et al. 1993). These factors have also
been included in the AJCC staging sys-
tem (American Joint Committee on
Cancer 2002). For local recurrence, prog-
nostic factors are, however, less well de-
fined. The most frequently cited signifi-
cant factors are status of the surgical
resection margin and tumour malignan-
cy grade, followed by patient age and lo-
cally recurrent presentation. In some of
the large series, tumour size, tumour lo-
cation in compartment, tumour site and
tumour depth have also been significant
(Table 2).
Prognostic factors can be classified as
patient, tumour or treatment related. Pa-
tient- and tumour-related factors cannot
be altered, and their principal role is to
provide information about the severity
of the disease so that a treatment strate-
gy can be devised. Treatment-related fac-
tors, including surgical margins, can be
directly influenced by the treating team
and are discussed in the sections “Surgi-
cal margins” and “Radiotherapy”.
Tumour malignancy grade is the fac-
tor that best measures a tumour’s biolog-
ical aggressiveness. A high malignancy
grade is generally accepted as a prognos-
tic factor for local recurrence (Table 2).
However, reports have been published in
which high grade has not been signifi-
cant for local recurrence (Gibbs et al.
1997, Pisters et al. 1996). A possible ex-
planation is that differences in RT ad-
ministration and the extent of the surgi-
cal margins between low- and high-
grade tumours confound multivariate
analysis as also the interpretation of his-
tological grades.
A number of studies report ad-
vanced age of the patient as a significant
factor for local recurrence (Table 2). The
largest studies have used cut-off values
of 50 and 64 years (Pisters et al. 1996,
Zagars et al. 2003). The causal effect of
age on local recurrence has not, however,
been satisfactorily explained. One sug-
gestion is that, in the detailed analysis of
surgical margins in millimetres, elderly
patients would not have been operated
27
on with as wide margins as younger pa-
tients, but data on this issue are lacking.
Prior local recurrence of STS is
strongly associated with the develop-
ment of metastases and tumour mortali-
ty, and it is a negative prognostic factor
(Lewis et al. 1997). Prior local recurrence
is also a prognostic factor for subsequent
local recurrence. This issue is discussed
in detail in the section “Surgery for local-
ly recurrent disease”.
The impact of tumour size on local
recurrence was documented as a signifi-
cant prognostic factor in one of the larg-
est series published, that of Zagars et al.,
in which the cut-off size was 10 cm (Ta-
ble 2). However, many large studies con-
clude that tumour size does not affect lo-
cal recurrence (Table 2). This may be
explained by the association of size with
the surgical margins achieved, regarded
by multivariate analysis. Thus, for local
control, the importance of tumour size is
mainly treatment related, and is empha-
sised in the head and neck region where
the extent of resection is more limited.
The depth of the tumour and its as-
sociation with anatomical structures that
resist tumour spread is of paramount
importance to the surgeon, especially
when RT is not delivered.  A system for
the surgical staging of musculoskeletal
sarcoma based on tumour malignancy
grade and the concept of the surgical
compartment was described in 1980
(Enneking et al. 1980). Although this
system has been replaced by newer ones
with better survival predictability
(Wunder et al. 2000), it still forms the
basis for the designation of surgical
treatment. However, the depth of the tu-
mour and its location in the compart-
ment are no longer considered so impor-
tant due to the more liberal use of RT.
The majority of multivariate analyses
give no data on tumour depth or com-
partment, and these factors are often ei-
ther analysed together with factors such
as tumour site or are defined differently,
thus preventing objective comparison
(Table 2).
The concept of tumour location
from the surgeon’s point of view has
been refined still further. By definition, a
subcutaneous tumour is located in sub-
cutaneous tissue with the deep fascia un-
opened and without tumour invasion; an
intramuscular tumour is located inside a
muscle, with no involvement of muscle
fascia and has not been subjected to pri-
or surgery; an extramuscular tumour
grows through or into the deep fascia, or
is deep-seated and grows partly or totally
outside muscles (Rydholm et al.1991).
Subcutaneous tumours recur locally in
5-7.5% of patients (Gibbs et al. 1997, Ry-
dholm et al. 1991). Intramuscular tu-
mours treated with myectomy alone
have recurred locally in 6% of patients
(Rydholm et al. 1986). Extramuscular
tumours have been shown to have the
worst prognosis in terms of survival and
local recurrence (Gibbs et al. 1997, Ryd-
holm et al. 1991).
Patients with STS in the extremities
have a better prognosis than those with
STS in the deep trunk (Zagars et al. 2003,
Dinges et al. 1994). Retroperitoneal sar-
comas are not usually analysed with STS
of the extremities or trunk owing to
their anatomic peculiarity, lack of surgi-
cal boundaries and asymptomatic
growth of huge masses. A local recur-
rence rate of 88% has been reported in
retroperitoneal STS (Gronchi et al.
2004). Head and neck sarcomas recur lo-
cally in 41% of patients.  These sarcomas
thus have poorer local control than STS
of the extremities (Bentz et al. 2004).
In large series, the histopathological
subtypes MPNST and fibrosarcoma (Pis-
ters et al. 1996), and MPNST, MFH and
epithelioid sarcoma (Zagars et al. 2003)
have been more likely to recur locally.
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Table 2.  Prognostic factors for local recurrence by multivariate analysis in large series
2.13 Outcome
There are numerous reasons why it is
difficult to make an objective compari-
son of treatment results between centres.
First, STS is a relatively rare disease and
thus patient series are collected over long
periods of time that may include several
treatment strategies. Second, there is a
large number of histological subtypes.
Third, different centres use different
classification and grading systems.
Fourth, STS can be located in almost any
site of the body and, moreover, within
the site, tumour location varies from in-
tra- to extracompartmental. All these
factors affect the severity of the disease.
At the moment, there is no standardised
practice of reporting the characteristics
of patients and, what is more, the inclu-
sion criteria for the series differ.
The definitive surgical procedure is
the single most important therapeutic
manoeuvre for the outcome of a STS pa-
tient. However, systems for evaluating
surgical margins vary. To compare the
effectiveness of nonsurgical treatment,
both the stage and the surgical proce-
dure must be identical (Enneking et al.
2003). For example, it is not appropriate
to compare the effectiveness of RT for a
deep extracompartmental high-grade tu-
mour treated with intralesional opera-
tion with the effectiveness of RT for a su-
perficial intracompartmental high-grade
tumour treated with wide excision. Fi-
nally, the indications for adjuvant RT
and chemotherapy differ from one cen-
tre to another.
The oncological outcome measures
commonly used are local recurrence-free
survival (LRFS), disease free-survival
(DFS), metastasis free-survival (MFS),
disease-specific overall survival (DSOS)
and overall survival (OS). All these
measures can be reported as actual
events or estimated by the Kaplan-Meier
method. In STS, a commonly used cut-
off point is five years. The uniform fac-
tors measuring limb salvage are amputa-
tion or limb salvage rates. Amputation
rate and LRFS together give a relatively
good impression of the quality of treat-
ment from the surgeon’s point of view.
Amputation rates from the 1950s to
1970s were 37–50%, with local recur-
rences of 9–31% (Table 3, Shiu et al.
1975, Enneking et al. 1981, Abbas et al.
Author Years Institution n Grade Size Comp LR SM D Age Site
Zagars et al.
2003
1960-
1999
M.D. Anderson 
Hospital, Houston
1225 0.003 >10 cm
0.019
nd <0.001  <0.001 nd  >64    
<0.001
<0.001
**
Pisters et al.
1996
1982-
1994
Memorial Sloan-
Kettering Cancer 
Center, NY
1041 n.s. n.s. nd <0.001 <0.001 n.s. > 50 
0.016
n.s.
Trovik et al. 
2000
1986-
1991
Scandinavian 
Sarcoma Group
559 0.002 n.s. nd nd <0.001 nd n.s n.s
Coindre et 
al. 1996
1980-
1989
French Federation 
of Cancer Centers
546 <0.001 n.s. nd nd <0.001* 0.01 n.s. nd
Stefanovski 
et al. 2002
1985-
1997
Centro di 
Riferimento 
Oncologico, Aviano
395 0.04 n.s. nd nd  <0.01 nd n.s. n.s.
Vraa et al. 
1998
1979-
1993
University Hospital 
of Aarhus
316 0.01 n.s. <0.001 nd 0.03 n.s. 0.004 n.s
** head and neck or deep trunk
*  local excision vs more extensive operation
decimals are p-values, n.s. = non-significant, nd = no data
Comp = compartment, LR = local recurrence, SM = surgical margins, D = depth
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1981, Rosenberg et al. 1982). The fre-
quent adoption of RT in the 1980s
brought amputation rates down to 6–
30%, usually to less than 15%, with local
recurrences of 6–23% (Table 3, Karak-
ousis et al. 1991, Rydholm et al. 1991,
Pisters et al. 1996, Vraa et al. 1998, Trovik
et al. 2001, Lohman et al. 2002). These
results imply that limb-salvage treat-
ment, when adequately performed, is as
safe as amputation in terms of local con-
trol. However, there have been no major
changes in MFS or OS for many years
(Table 3). This situation is attributed to
the fact that the type of local treatment,
provided that it is performed adequately
(whether by conservative surgery with
RT or amputation), is incapable of af-
fecting the systemic dissemination of
STS. A MFS rate of 78% and DSOS rate
of 81% at five years were reported in one
of the largest series published (Pisters et
al. 1996).
Author Institution no. yr LOC Grade RT AMP LR DFS MFS DSOS 
Shiu et al. 
1975
Memorial Sloan-Kettering 
Cancer Center, NY
297 1949-
1968
lower 
extr
high and 
low
no 47 18 40^^ 74^^ 55^ yes
Enneking et 
al. 1981
University of Florida 40 1963-
1978
thigh 31 high, 9 
low
no 50 15 58 60 60 yes
Lindberg et 
al. 1981
M.D. Anderson Hospital, 
Houston
200 1963-
1977
extr high and 
low
yes 15 20 56 75 54^ nd
Abbas et al. 
1981
Roswell Park Memorial 
Institute, Buffalo
117 1965-
1975
extr majority 
high
yes 38 31 nd nd 50^ yes
Rosenberg 
et al. 1982
National Cancer Institute, 
Bethesda 
43 1975-
1981
extr 35 high, 8 
low
yes 37 9 79 88 88 nd
Suit et al. 
1988
Harward Medical School, 
Boston
180 1971-
1985
extr high and 
low
yes 3 13 70 nd nd nd
Karakousis 
et al. 1991
Roswell Park Memorial 
Institute, Buffalo
144 1977-
1986
extr high and 
low
yes 6 6 61 nd 71 yes
Rydholm et 
al. 1991
University Hospital, Lund, 
Sweden
119 1980-
1986
extr 101 high, 
18 low
yes 10 11 nd nd 82 no
Coindre et 
al. 1996
French Federation of 
Cancer Centers
331 1980-
1989
extr majority 
high
yes 4 29 nd 60 69^ no
Pisters et al. 
1996
Memorial Sloan-Kettering 
Cancer Center, NY
1041 1982-
1994
extr 678 high, 
363 low
yes 13 17 68 78 81 yes
Gibbs et al. 
1997
University of Chicago 62 1975-
1993
extr* 46 high, 
16 low
yes 6 5 81 nd 87 yes
Vraa et al. 
1998
University Hospital of 
Aarhus, Denmark
222 1979-
1993
extr high and 
low
yes 30 21 nd nd 74 yes
Trovik et al. 
2001
SSG register, Scandinavia 459 1986-
1993
extr high yes 15 23 46 56 nd no
Choong et 
al. 2001
St Vincent's Hospital, 
Melbourne
132 1980-
1995
extr low yes nd 8 nd 95 92 no
Lohman et 
al. 2002
M.D. Anderson Hospital, 
Houston
100 1992-
1997
upper 
extr
70 high, 
30 low
yes 13 13 nd nd 82 yes
yr = years, LOC = location, RT = radiotherapy, AMP = amputation %, LR = local recurrence %                      
DFS = disease-free survival % at five years, MFS = metastasis-free survival % at five years                   
DSOS = disease-specific overall survival %
* all subcutaneous    ^ not disease-specific overall survival    ^^ during total follow-up
Loc 
rec 
incl
Table 3.  Results of treatment in 15 studies of soft tissue sarcoma of the extremities
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3. Chest wall reconstruction
3.1 Tumours of the chest wall
A tumour of the chest wall can originate
primarily within the chest wall, develop
as a local recurrence from a previously
excised chest wall lesion, present as met-
astatic disease from a distant site or
manifest itself as a primary tumour from
intrathoracic organs infiltrating the chest
wall. Primary chest wall tumours ac-
count for about 5% of thoracic neo-
plasms and for 1–2% of all primary tu-
mours (Perry et al. 1990). In sarcomas,
the chest wall accounts for 6–7% of the
total (Walsh et al. 2001).  Approximately
45% of primary malignant tumours of
the chest wall arise from soft tissue sar-
comas and 55% appear in cartilaginous
or bony tissue (Incarbone et al. 2001).
The most frequent diagnosis is sarcoma,
and less frequently plasmacytoma or
lymphoma. Chondrosarcoma is the most
common primary bone chest wall sarco-
ma (Figure 3). The chest wall is also a
site of radiation-induced sarcomas
(Wiklund et al. 1991, Chapelier et al.
1997). Breast cancer recurrence as a tu-
mour in the chest wall is common. With
modern treatment local recurrences oc-
cur in 5–22 % of the breast cancer pa-
tients (Huston et al. 2005). In broncho-
genic carcinoma, direct chest wall
invasion occurs in 5–8% of patients
(Facciolo et al. 2001). Extensive full-
thickness chest wall resections are most
frequently performed in patients with
primary sarcomas or local recurrence of
breast cancer (Incarbone et al. 2001,
Vandeweyer et al. 2002).
3.2 Methods for chest wall
reconstruction
The goal of chest wall reconstruction is
stability, water- and air-tight closure, and
an acceptable cosmetic appearance. Soft
tissue coverage can be attained in various
ways. Small defects can be closed directly
Figure 3. Patient with chondrosarcoma in the chest wall.
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but larger defects are reconstructed with
flaps. In the early days of reconstruction,
local skin flaps were used and, of these,
the contralateral breast flap is still in use
today (Wysocki et al. 2004), although it
is not preferred by plastic surgeons. The
pedicled latissimus dorsi muscle was in-
troduced for chest wall reconstruction in
1950 (Campbell 1950) and, together
with its modifications, has been in regu-
lar use ever since. The pedicled omental
transposition flap has also been used
with success for reconstruction, especial-
ly for infected sternotomy wounds
(Hultman et al. 2002).
The regional pedicled muscular or
musculocutaneous flap has been the first
choice for soft tissue coverage of a chest
wall defect, and flaps such as the latis-
simus dorsi, vertical rectus abdominis
(VRAM), transverse rectus abdominis
(TRAM), and pectoralis, serratus and ex-
ternal oblique muscles have commonly
been employed (Arnold et al. 1996, Man-
sour et al. 2002, Mathes et al. 1995, Sam-
uels et al. 1993). Multiple local or pedi-
cled flaps have also been applied to cover
extensive defects (Chang et al. 2004).
The choice of flap depends on the loca-
tion of the tumour, the size of the defect,
and the availability of autogenous graft
material. However, a pedicled flap can-
not be used in all patients for several rea-
sons. Local options may already have
been used, the pedicle or flap may have
been damaged by previous operations or
RT, or the flap may be of inadequate size
to cover the defect. Harvesting a flap on
the abdominal or chest wall area may
also cause additional impairment in
breathing. The larger the defect, the
greater the need for microsurgical tech-
niques. In a large, 200-patient series with
chest wall resection, the frequency of free
flap reconstructions was 9% (Mansour
et al. 2002). In a series of 20 free flaps for
full-thickness chest wall reconstruction,
myocutaneous rectus abdominis flaps
and fillet extremity free flaps were used
(Cordeiro et al. 2001). Other free flaps
employed for chest wall reconstruction
include the latissimus dorsi and omen-
tum (Al-Kattan et al. 1995, Losken et al.
2004, Chang et al. 2004).
Full-thickness chest wall resection
causes a defect in which pleural cavity is
open and the vital intrathoracic organs
are exposed. Bony stability has to be re-
stored in wide defects  to avoid paradoxal
respiratory movement and, hence, im-
paired respiratory function, without lim-
iting normal breathing. It has been
found that defects larger than 5 cm need
stabilisation of the bony chest wall (Mc-
Cormack 1989). This has been achieved
in various ways, for example, with autol-
ogous free fascial grafts (Watson et al.
1947) and rib grafts (Bisgard et al. 1948),
which long constituted the basis for re-
construction. Strips and plates of metal,
stainless steel, tantalum and fibreglass
have also been used, though today syn-
thetic materials are preferred. Marlex®
mesh was documented as relatively safe in
a retrospective series of 101 patients with
full-thickness chest wall resection; in 40
of the patients stability was achieved with,
and in 61 of them without, Marlex mesh.
Infection developed in 5% of the Marlex
group patients, but the mesh did not need
to be removed. The length of ventilatory
support was shorter in the Marlex group
(Kroll et al. 1993). Other synthetic mate-
rials commonly used are Vicryl® mesh,
Prolene® mesh, polytetrafluoroethylene
(PTFE) patch (Gore-Tex®), and “shield”
or “sandwich” prostheses (methyl metacr-
ylate sandwiched between two sheets of
prolene mesh), or their combinations
(Nash et al. 1991, Shiba et al. 1988, An-
derson et al. 1994, Sabanathan et al.
1997). The “shield” prosthesis offers
good stability, but complications due to
loosening and displacement of the pros-
thesis have been documented (Jönsson
et al. 1998). A type of graft recently de-
scribed is the iliac bone allograft, which
has the advantage that it integrates with
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the host patient’s living tissue (Cara et al.
1993, Garcia-Tutor et al. 2004). However,
agreement about the method of recon-
struction is lacking and decisions are
mainly based on the surgeon’s prefer-
ence.
The pedicled tensor fasciae latae
(TFL) musculocutaneous flap has been
used for lower abdominal wall recon-
struction since its description in 1934
(Wagensteen 1934). Although use of this
flap is limited by the arch of rotation to
the infraumbilical region, its application
as a myocutaneous free flap (Hill et al.
1978) has made reconstructions of the
supraumbilical region possible (O’Hare
et al. 1983, Cafee et al. 1983, Williams et
al. 1997). Recently, its use was described
in full-thickness chest wall defects in a
series of seven patients (Heitmann et al.
2000). To our knowledge, there are no
reports from larger series about chest
wall reconstruction with the TFL free
flap, which can be very large and yet its
harvesting does not affect the patient’s
respiratory function.
3.3 Survival of patients and results
of surgery after chest wall resection
Previous studies have shown that chest
wall resection is seldom curative in pa-
tients with breast cancer recurrence in
the chest wall. Long-term survival may
be poor in such patients, yet the opera-
tion may offer them remarkable pallia-
tion, since they may suffer intense local
pain, bleeding and discharge, infection,
fetor, continuing tumour growth, oede-
ma or paralysis of the upper extremity
due to the compression of motor nerves.
Such patients may be candidates for pal-
liative resection and reconstruction. In
one series of 38 patients with breast can-
cer recurrence who underwent full-
thickness chest wall resection and, in
most cases, reconstruction with a pedi-
cled flap, the overall survival rate was
18% at five years (Downey et al. 2000);
in another series of 13 similar patients it
was 31% (Nash et al. 1991). In a series of
98 patients with less complex breast can-
cer recurrence who underwent mainly
soft tissue resection, the overall survival
rate was 56% at five years (Dahlstrom et
al. 1993). In a series of 15 patients with
breast cancer recurrence treated mainly
with soft tissue resection and recon-
struction with pedicled flaps, the surviv-
al rate was 13% even though the post-
operative margins were tumour free
(Vandeweyer et al. 2002). A disease-free
interval longer than two years after pri-
mary therapy for breast cancer results in
significantly longer survival after radical
treatment of chest wall recurrence
(Faneyte et al. 1997).
Patients with sarcoma in the chest
wall have a better prognosis and for
them surgery may be curative. In a series
of 51 patients with localised sarcoma in
the thoracic wall who underwent full-
thickness resection, the survival rate was
64% at five years. In the treatment of
chest wall sarcomas, wide margins re-
main the most important surgical objec-
tive, and the extent of resection should
never be compromised because of con-
cern about closing the defect (Walsh et
al. 2001). This has also been documented
in a series of 28 patients with primary,
locally recurrent and metastatic sarco-
mas with 59% survival (Perry et al.
1990). In a series of 15 patients with
postirradiation sarcoma who underwent
bony chest wall resection, survival was
48% at five years (Chapelier et al. 1997).
In chondrosarcomas, survival was 64%
but in osteosarcomas only 15% (Burt et
al. 1992).
In a recent series of chest wall resec-
tions, perioperative mortality was 0–17%
(Cordeiro et al. 2001, Arnold et al. 1996,
Mansour et al. 2002, Al-Kattan et al.
1995, Cohen et al. 1996). From most re-
ports, it would seem that chest wall re-
section is a relatively safe procedure.
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4. Surgery in dermatofibro-
sarcoma
Traditionally, the recommended treat-
ment for dermatofibrosarcoma has been
wide surgical excision with gross mar-
gins of at least 3 cm (McPeak et al. 1967,
Rutgers et al. 1992, Bendix-Hansen et al.
1983, Roses et al. 1986). In a literature
review comprising 913 cases of der-
matofibrosarcoma, local recurrences were
reported in 32–76% (mean 52%) of pa-
tients after an operation with undefined
surgical margins; after wide excision, lo-
cal recurrences occurred in 0–60%
(mean 13%) of the patients (Rutgers et
al. 1992).
During the last 10 years, more infor-
mation about the microscopic tumour-
free margins has been gathered through
reports about micrographic surgery (Ah-
Weng et al. 2002, Gloster et al. 1996,
Ratner et al. 1997, Haycox et al. 1997),
originally developed by Dr Frederick
Mohs at the University of Wisconsin. In
Mohs surgery excision is guided by fro-
zen sections in order to minimise tissue
defects and to remove the tumour com-
pletely. At some centres, Mohs micro-
graphic surgery has been the treatment of
choice for DFSP. According to a review of
169 patients with a relatively short follow-
up time, the average recurrence rate in
patients treated with Mohs surgery was
2.4% (Haycox et al. 1997); in another re-
cent review, of 136 patients with a follow-
up time of more than five years, the re-
currence rate was 6.6% (Snow et al.
2004). In comparison, excellent results
with no recurrences were reported in a
large, retrospective series of 117 patients
treated with 5-cm-wide excision margins
with a mean follow-up time of more than
5 years (Arnaud et al. 1997). Traditional
excisional surgery is still the preferred
procedure, but excellent results can also
be achieved with a selective combination
of excisional and micrographic surgery
(DuBay et al. 2004).
On certain occasions, albeit infre-
quently, adequate surgical margins can-
not be obtained by conservative surgery.
RT may be beneficial in patients with in-
tralesional margins (Haas et al. 1997,
Lindner et al. 1999, Ballo et al. 1998), but
its definitive role still remains unclear
due to the lack of randomised trials.
DFSP is characterised by chromosomal
rearrangements resulting in the produc-
tion of PDGF (Simon et al. 1997). A
new, molecularly targeted drug, the se-
lective tyrosine-kinase inhibitor imatinib
(Glivec®), functions as an inhibitor of
PDGF receptors, thus blocking this auto-
crine stimulation. Recent case reports
document promising results in the treat-
ment of advanced DFSP with imatinib
(Maki et al. 2002, Rubin et al. 2002, Price
et al. 2004).
Reports on the use of wide excisions
have mainly concentrated on gross surgi-
cal tumour-free margins (Roses et al.
1986, Arnaud et al. 1997) or, histologi-
cally, on the presence of tumour tissue in
the cut surfaces (Bowne et al. 2000).
However, owing to the extremely infil-
trative growth pattern of DFSP, it is felt
that terms such as a “microscopically
positive” or “negative” margin are not
sufficiently accurate to verify the radical-
ity of the operation. Detailed informa-
tion about a histological tumour-free
margin, measured in millimetres, and
about its effect on the local recurrence
rate, is needed in order to set recommen-
dations for treatment with excisional
surgery.
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AIMS OF THE STUDY
Studies I and III: to evaluate the justification for limb-saving multidisciplinary treat-
ment of extremity soft tissue sarcomas (STS) and to report the results achieved by the
treatment protocol of Soft Tissue Sarcoma Group at Helsinki University Central Hos-
pital.
Study II: to compare genetic aberrations in primary soft tissue sarcomas and their lo-
cal recurrences and to evaluate the genetic changes occurring during local tumour
progression.
Study IV: to evaluate the suitability of microvascular flaps, especially TFL, for the re-
construction of extensive full-thickness defects of the chest wall caused by excision of
malignancies.
Study V: to report the results of 40 patients with dermatofibrosarcoma treated by sur-
gical excision, with special reference to gross and histological margins.
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MATERIALS AND METHODS
In Study III, 95 patients with a soft
tissue sarcoma located in the upper ex-
tremity were referred to the sarcoma
group between August 1987 and August
1999. Excluded from the survival analysis
were seven dermatofibrosarcomas, six
patients with haematogenous metastases,
one extraskeletal Ewing sarcoma that was
not operated on, and one patient who re-
fused any treatment. Eighty patients
were operated on with curative intention
(Table 4).  Tumour size ranged from 0.5
to 22.0 cm, with a median size of 5.0 cm.
There were 67 (84%) high-grade and 13
(16%) low-grade tumours. The most
common histological types were MFH,
synovial sarcoma, leiomyosarcoma, li-
posarcoma, fibrosarcoma and epitheloid
sarcoma. Sixty-five patients were referred
for primary tumour and 15 for local re-
currence. The referral status of primary
tumours before the operation was: vir-
gin, fine-needle, core-needle or incision-
al biopsy in 41 and curatively intended
excision in 24 patients. Of the patients
referred for local recurrence, the number
of local recurrences before referral was:
one in five patients, two in five, three in
one, five in one and eight in one patient.
1.1 Treatment guidelines
The diagnosis was confirmed by cytolog-
ical and histological needle biopsies. Tu-
mour malignancy was graded on a four-
point scale, and any former histological
samples that may have been related to
the tumour were re-examined. Surgical
history was evaluated in detail. Preopera-
tively, CT, MRI and/or ultrasound scan
were performed on the tumour area. All
patients had a chest x-ray, and a chest CT
scan was a routine procedure for patients
with high-grade tumours. The extent of
1. Clinical material in soft tis-
sue sarcomas of the extremi-
ties (Studies I and III)
The patient series in Studies I and III con-
sist of patients treated by the Multimodal-
ity Soft Tissue Sarcoma Group of Helsinki
University Central Hospital (HUCH) ac-
cording to the group’s protocol. The main
guidelines for treatment comply with
those recommended by the SSG. Data on
patients were prospectively recorded and
retrospectively collected in the STS regis-
try of HUCH for research purposes.
In Study I, 130 patients with STS lo-
cated in the lower limb were referred to
the sarcoma group between August 1987
and November 1994.  For survival analy-
sis, we included patients with local dis-
ease who were operated on with curative
intention. Excluded were three der-
matofibrosarcomas, four atypical lipo-
mas, one Kaposi sarcoma, 14 patients
with haematogenous metastases and two
patients with lymph node metastases.
The number of patients thus remaining
for survival analysis was 106 (Table 4).
Tumour size was recorded as the longest
diameter, with a median size of 7.0 cm
(range, 0.5 to 35.0 cm). There were 77
(73%) high-grade and 28 (26%) low-
grade tumours; in one tumour the grade
was unclassified. The most common his-
tological types were MFH, leiomyosarco-
ma, liposarcoma and synovial sarcoma.
Eighty-seven patients were referred for
primary tumour and 19 for local recur-
rence. The referral status of primary tu-
mours before surgery was: virgin, fine-
needle, core-needle or incisional biopsy
in 41 and curatively intended excision in
46 patients. Of the patients referred for
local recurrence, the number of local re-
currences before referral was: one in 14,
two in three and three in two patients.
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the operation was then planned on the
basis of the data thus acquired.
The excised tissue was sent immedi-
ately without preservation to the pathol-
ogist, who examined the postoperative
surgical margins. These were defined as
compartmental when an intracompart-
mental tumour was resected en bloc with
the involved muscle compartment. For
intramuscular tumours, myectomy was
considered as radical as compartmental
surgery. Postoperative margins were con-
Figure 4. Resection of tumours according to compartment
sidered wide when the thickness of nor-
mal tissue separating the tumour from
the excision margin was at least 2.5 cm
histologically. If the thickness was less,
the margin was considered marginal.
The excision was also considered wide if
the distance was less than 2.5 cm but an
intact anatomical barrier (intercompart-
mental, deep or muscle fascia) separated
the tumour from the excision margin
(Figure 4). If the tumour was cut
through, visible tumour tissue was left
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tumour
wide marginal intralesional
follow-up RT re-excision re-excision or amputation
follow-up wide see: wide or marginalmarginal
RT
follow-up
follow-up
RT = radiotherapy
on the operation area or histological tu-
mour-free margins were not achieved,
the margin was considered intralesional.
The aim of the surgery was to
achieve wide or compartmental excision
margins with preservation of the limb
and its function. In the event of marginal
resection margins, post-operative RT was
recommended (Figure 5). A few patients
were given preoperative RT for tumours
judged to be inoperable. Excision of the
tumour often led to extensive tissue de-
fects. Exposure or defects of bone, major
joints or tendons and also large cavities
were managed with reconstructive sur-
gery. The limb was amputated only if
there was extensive infiltration of a ma-
jor nerve, bone or joint by the tumour,
and not even marginal resection was fea-
sible. In these cases, a great risk of local
recurrence or of poor limb function fa-
voured amputation. For intralesional
margins, re-operation was performed
when feasible.
Adequate treatment was defined as
wide / compartmental surgery alone or
marginal surgery combined with post-
operative RT. Chemotherapy was not rou-
tinely used except for extraskeletal Ewing
sarcomas or metastatic disease. Pulmo-
nary metastases, as also local recurrences,
were operated on when feasible.
2. Comparative genomic
hybridisation (Study II)
The study used paired samples of prima-
ry tumours and their local recurrences
for CGH analyses. The material consisted
of 20 samples of primary tumours and
20 samples of local recurrences from 20
patients with STS whose primary tu-
mour and its corresponding, subsequent
local recurrence were studied by CGH.
The patients were selected from the reg-
istry of the Soft Tissue Sarcoma Group at
HUCH. The inclusion criteria were a dis-
ease-free period exceeding four months
from the operation of the primary tu-
mour to the detection of the local recur-
rence, and excision of all macroscopic
tumour mass in the first operation. The
exclusion criteria were delivery of any
chemotherapy and/or RT for the prima-
ry tumour, and preoperative chemother-
apy and/or RT for the local recurrence.
The most representative block of tu-
mour tissue was chosen for CGH analy-
sis by light-microscopic examination.
DNA was isolated by standard meth-
ods (Miller et al. 1988, Sambrook et al.
1989). CGH was performed as described
earlier (Larramendy et al. 1997, El-Rifai
Figure 5. Treatment algorithm for soft tissue sarcomas at Helsinki University Central
Hospital. Excluded from this protocol are dermatofibrosarcomas, Kaposi and visceral
sarcomas
38
et al. 1997). Chromosomal regions were
interpreted as overrepresented when the
ratio of tumour DNA to normal DNA
was higher than 1.17 (gains) and under-
represented when the ratio was lower
than 0.85 (losses). These limits were
based on our earlier findings and on
control experiments: each experiment
included a negative control (two differen-
tially labelled normal human DNAs) and
a positive control (a tumour sample with
known DNA sequence copy number
changes). Gains exceeding the 1.5 limit
were termed high-level amplifications
(Knuutila et al. 1998).
3. Resections and reconstruc-
tions of the chest wall
(Study IV)
The series consisted of 26 patients who
underwent full-thickness chest wall resec-
tion and reconstruction with a free flap at
the Department of Plastic Surgery, Hel-
sinki University Central Hospital, be-
tween 1988 and 2001. These patients re-
quire one of the most complicated
treatments and have the poorest progno-
sis of all patients with soft tissue tumours.
The indication for operation was a
tumour that required extensive soft tis-
sue reconstruction after excision in a sit-
uation in which use of a conventional
pedicular flap was not feasible. The dis-
ease requiring reconstruction was a STS
in eight patients, chondrosarcoma in
five, breast cancer recurrence in eight,
desmoid tumour in two, carcinoma me-
tastases in two and bronchopleural fistu-
la in one patient. Sixteen patients were
operated on with curative intention and
10 palliatively to relieve serious local
symptoms. Chest wall resection and soft
tissue reconstruction with a free flap
were performed in the same operation.
When necessary, the chest wall was stabi-
lised with free rib grafts or synthetic
mesh. Usually one or two ribs (e.g. ribs
number 6 and 8, or 5 and 7) from the af-
fected side were harvested for grafts. The
rib grafts, which were fixed to the bony
chest wall with cerclage wires, were placed
such that the bony defect was divided into
smaller areas and the convex shape of the
chest was maintained. Polypropylene
mesh was used for stabilisation either sep-
arately or in conjunction with rib grafts.
The mesh was always sutured both to rib
grafts and to the chest wall.
To reduce the operating time, har-
vesting of the flap and resection (includ-
ing preparation of the recipient vessels)
were performed simultaneously. Once
adequate recipient vessels had been
found, the vascular supply to the flap
was divided. Microvascular anastomoses
were established in major vessels in axil-
lary, subclavial, sternal, cervical, or in-
guinal areas either end-to-end or end-to-
side. The anastomoses were performed
under magnifying operation glasses with
7-0 or 8-0 sutures. In cases in which the
pedicle did not reach the recipient ves-
sels, a great saphenous vein loop (Freed-
man et al. 1989)  was used to provide the
artery and vein for the TFL free flap. The
vessels were flushed frequently with
heparin-Ringer’s sterile solution.
Anticoagulation medication during
and after the operation consisted of low
molecular heparin 2500 IU administered
subcutaneously twice a day. The medica-
tion was started on the first preoperative
day and was discontinued when the pa-
tient was ambulatory, usually 7-12 days
after the operation. Oral anticoagulation
medication was not given.
4. Dermatofibrosarcomas
(Study V)
Forty patients with DFSP were referred
to the Soft Tissue Sarcoma Group be-
tween August 1987 and February 2001.
Among patients with STS, the surgical
treatment of these patients is non-com-
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plicated and their prognosis is good. Ra-
diological (excluding chest CT) and oth-
er examinations as described in Studies I
and III were conducted before the opera-
tion. The excision, which was made en
bloc, was usually planned with 3-cm
macroscopic margins in the skin, subcu-
taneous tissue or muscle. In patients in
whom the tumour was located in the
skin only, and abundant margins of sub-
cutaneous tissue were likely to be
achieved, the deep fascia was not violat-
ed. If the tumour extension in depth was
uncertain, especially in local recurrences,
the deep fascia was excised together with
underlying muscle. Postoperative surgi-
cal margins were defined as wide, mar-
ginal or intralesional (as described in
Studies I and III). The aim of the surgery
was wide excision. In patients in whom
wide margins would have called for sac-
rifice of vital neurovascular structures,
the margins were left as marginal and
the increased risk of local recurrence was
accepted. All wounds were closed prima-
rily, and the soft tissue defects were re-
constructed with skin grafts or with lo-
cal, pedicled or microvascular flaps when
necessary. Oncological treatment such as
RT or chemotherapy was not used.
During the operation, the excised
specimen was marked at all cut surfaces
with sutures. Frozen sections were ob-
tained in the event of suspicious mar-
gins. At the Department of Pathology all
margins of the formalin-fixed specimens
were marked with ink or other stains be-
fore taking an ample number of samples
for histological examination. Depending
on the size of the specimen, the number
might be anything up to 20. Several paral-
lel samples were taken from sites where
the tumour seemed to be closest to the
margin macroscopically. The tumour-free
margins were measured from histological
slides, in recent cases with a computerised
system (Pathfinder, Compucyte Corpora-
tion, MA, USA). If the microscopic mar-
gin was less than 1.5 cm, re-operation was
performed when feasible.
All 40 patients with DFSP were oper-
ated on. Two of the tumours had fibrosa-
rcomatous changes. The tumour size,
which was recorded as the longest diam-
eter, ranged from 1.0 to 9.5 cm, with a
median size of 2.7 cm. Twenty-seven pa-
tients were referred for primary and 13
for locally recurrent tumour. Of the pa-
tients with primary tumours, 20 were re-
ferred after marginal excision, six after
incisional biopsy and one virginally. Of
those with local recurrences, two were
referred for the first, 10 for the second
and one for the third recurrence. None
of the patients presented with distant
metastases.
5. Statistical analysis (Studies
I–V)
Disease-specific overall survival (DSOS),
local recurrence-free survival (LRFS),
metastasis-free survival (MFS) and dis-
ease-free survival (DFS) rates were cal-
culated according to the method of Kap-
lan and Meier (Studies I, III, IV and V).
A death occurring for reasons other than
sarcoma was considered as lost to follow-
up. Univariate analysis for clinical prog-
nostic factors was performed by the Cox
regression model. Variables found to be
significant in univariate analysis were in-
troduced into the multivariate model.
The multivariate analysis was performed
by the Cox proportional hazard method
(Studies I and III). Outcome measures
refer to five-year survival. A p-value less
than 0.05 was considered statistically sig-
nificant. All p-values refer to overall out-
comes and not to specific points in time.
The difference in copy number aberra-
tions between primary tumours and
local recurrences was calculated and
statistically analysed by a paired t-test
(Study II).
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flaps, 17 skin flaps, 42 split-thickness
skin grafts, one forearm replantation and
two humeroscapular resections accord-
ing to Tikhoff and Linberg (Sugarbaker
et al. 1992, Table 5). The most common
free flap was TFL (n=22) followed by lat-
issimus dorsi muscle (n=20). The success
rate for microvascular flaps was 96.4%.
In the study on chest wall resections
(Study IV) there were eight sternal, five
lateral, and eight thoraco-abdominal
full-thickness resections of the chest
wall; in addition, five patients underwent
extended forequarter amputation with
resection of the ribs. The average
number of ribs resected was 3.9, the
mean area of soft    tissue resection 503
cm2 and the mean  diameter of resection
28 cm. The chest was stabilised with syn-
thetic mesh in eight patients and with
free rib grafts in nine patients. For recon-
structions of soft tissue, see Table 5. In
seven thoraco-abdominal resections, the
TFL flap had to be placed so proximally
that the pedicle vessels could not reach
the inguinal area and a great saphenous
vein loop was used. There was no peri-
operative mortality or flap losses. The
average operation time was seven hours
(range 3 1/2–10 hours) and periopera-
tive blood loss 3800 ml (range 700–7000
ml). The median treatment period in the
intensive care unit was six days (range 0–
35 days) and in the surgical ward 20 days
(range 10–39 days). Four patients re-
quired a tracheostomy due to prolonged
ventilatory support, and five patients re-
quired revision of the microvascular
anastomosis. Six patients had to be oper-
ated on due to healing problems in the
resection or the flap donor site. In one
patient, a postoperative hernia was re-
paired. One patient needed a free rib
graft owing to paradoxal movement of
the chest wall that caused severe ventila-
tory dysfunction. There were no chronic
RESULTS
1. Sarcomas of the extremities
(Studies I and III), Recon-
structions of the chest wall
(Study IV) and Dermatofibro-
sarcomas (Study V)
1.1 Procedures performed
The total number of patients treated in
the clinical studies (Studies I and III-V)
was 252. Of these, 106 presented with
STS in the lower limb, 80 with STS in the
upper limb, 26 with chest wall resection
due to various malignancies and 40 with
dermatofibrosarcomas (Table 4). Exclud-
ing those with desmoid tumours and
dermatofibrosarcomas, the number of
STS patients was 194. The operation was
excision and direct closure in 99 patients
(39%, Table 5). Twenty-five major am-
putations were performed as follows:
two forearm, five humeral, two humeral
exarticulations, one forequarter, five ex-
tended forequarter, one hemipelvectomy,
two femoral, three femoral exarticula-
tions, three below-knee and one distal
foot. In extremity sarcomas, the amputa-
tion frequency was 10% (lower limbs
9%, upper limbs 12.5%) and in thoracic
wall tumours 19%; there were no ampu-
tations in dermatofibrosarcoma patients.
Limb salvage was possible in 90% of all
patients.
Free flap reconstructions were re-
quired in all extended forequarter ampu-
tations and hemipelvectomies (n=6).
When direct closures and amputations
without reconstructions were excluded,
reconstructions were needed in 137 pa-
tients (53%). Reconstructive procedures
were required in the lower limbs in 45%,
in the upper limbs in 48%, in full-thick-
ness chest wall resections in 100% and in
DFSPs in 58% of the patients. There
were 56 microvascular flaps, 28 pedicled
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Table 4. Patient and tumour characteristics
Study no.           I          III           IV          V     All           %
Gender
Female 64 36 15 18 133 53
Male 42 44 11 22 119 47
Age
Median 55 57 61 45
Range    18-91     20-84     23-77     22-77
Histology
MFH 33 30 2 65        25.8
Dermatofibrosarcoma 40 40        15.9
Leiomyosarcoma 23 7 1 31        12.3
Synovial sarcoma 10 14 24          9.5
Liposarcoma 16 6 22          8.7
Sarcoma NOS 9 5 3 17          6.7
Fibrosarcoma 2 6 8          3.2
Breast cancer recurrence 8 8          3.2
Malignant schwannoma 4 1 5            2  
Epithelioid sarcoma 5 5            2
Chondrosarcoma 5 5            2
Extraskeletal sarcoma Ewing 4 4          1.6
Malignant hemangiopericytoma 3 1 4          1.6
Other 3 3          1.2
Extraskeletal chondrosarcoma 2 2          0.7
Clear cell sarcoma 2 2          0.7
Desmoid tumor 2 2          0.7
Extraskeletal osteosarcoma 1 1          0.4
Myxofibrosarcoma 1 1          0.4
Angiosarcoma 1 1          0.4
Lymphangiosarcoma 1 1          0.4
Alveolar soft-part sarcoma 1 1          0.4
Grade
High 77 67 9 153 63
Low 28 13 6 40 87 36
Unclassified 1 1 1
Site
Lower limb 106 8 114 45
Upper limb 80 9 89 35
Upper trunk 12 12 5
Chest wall, full-thickness 26 26 10
Lower trunk 7 7 3
Head and neck 4 4 2
Total number of patients 106 80 26 40 252
MFH = malignant fibrous histiocytoma, NOS = not otherwise specified
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                                                          Study        I      III       IV     V       All
Procedure
Direct closure 52 30 0 17 99
Amputation 10 12 5 27
     Minor 2 2
     Major 10 10 5 25
Skin graft 20 11 11 42
Pedicled or local skin flap 3 7 7 17
Pedicled muscular, musculocutaneous or 
fasciocutaneous flap 12 13 3 28
     Latissimus dorsi 9 1 10
     Brachioradial 1 1
     Pectoral 1 1
     Radial forearm 1 1
     Lateral arm flap 1 1
     Gastrocnemius 8 8
     Soleus 1 1
     Tensor fasciae latae 1 1
     Gluteus maximus 1 1
     Vastus lateralis 1 1
     Rectus abdominis 1 1
     Temporal 1 1
Microvascular flaps 18 10 26 2 56
     Radial forearm 4 1 5
     Latissimus dorsi 16 3 1 20
     Fibula 2 2
     Tensor fasciae latae plus crista iliaca 1 1
     Tensor fasciae latae 16 16
     Tensor fasciae latae plus rectus femoris 5 5
     Remnant leg 1 1
     Remnant forearm 2 2
     Gracilis 1 1
     TRAM 3 3
Forearm replantation after excision of elbow area
1 1
Nerve reconstruction 4 4
Main blood vessel reconstruction 1 1
Tikhoff-Linberg procedure 2 2
Number of patients   111* 80 26 40 257
* patients included in the survival analysis + 5 patients operated on palliatively
Table 5. Procedures performed in Studies I, III–V
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          LRFS 5           MFS 5          DFS 5      DSOS 2       DSOS 5
Study  I
follow-up, months              mean 56, median 55, range 2-221
survival % 79 72 63 87 76
Study III
follow-up, months              mean 74, median 72.0, range 10-177
survival % 79 68 62 91 75
Study IV
follow-up, months              mean 28, median 19, range 2 - 83
survival % 52               25*
Study  V
follow-up, months              mean 40, median 34, range 0.2 - 114
survival % 100 100 100 100 100
* overall survival
LRFS 5   = local recurrence-free survival at five years
MFS 5     = metastasis-free survival at five years
DFS 5     = disease-free survival at five years
DSOS 2  = disease-specific overall survival at two years
DSOS 5  = disease-specific overall survival at five years
deep infections or exposures of synthetic
mesh or rib grafts. Five patients required
further rehabilitation ate other hospitals.
All but three patients were able to return
home after the operation.
1.2 Outcome of patients
The survival of all patients in clinical
studies (Studies I and III-V) is presented
in Table 6.
For extremity sarcomas, LRFS at five
years was 79%, MFS 70%, DFS 63% and
DSOS 76%, as estimated by the Kaplan-
Meier method. Local recurrence devel-
oped in 32 patients (17%) and metastases
in 59 patients (32%). Forty-five patients
(25%) who were not lost to follow-up
died from their disease. For patients treat-
ed adequately, LRFS was 82% in lower
limbs and 90% in upper limbs, as com-
pared with 74% and 40%, respectively,
with inadequate treatment.
For patients with full-thickness chest
wall malignancies (Study IV) the overall
survival rate at two years was 52% and at
five years 25% (Table 6). The five-year
survival rate was 28% for sarcomas and
13% for breast cancer recurrences. There
was no postoperative mortality.
In patients with dermatofibrosarcoma
(Study V), there were no local recurrenc-
es, development of metastases or deaths
from disease during the follow-up time.
Table 6. Outcome of patients
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1.3 Clinical prognostic factors
The prognostic factors in STS of the ex-
tremities (Studies I and III) are present-
ed in Table 7. In lower extremity STS
(Study I), the prognostic factors tested in
univariate analysis were patient gender
and age, tumour malignancy grade, and
tumour size, site, compartmentalisation
and referral status (primary vs. locally
recurrent tumour). Prognostic factors
for the development of local recurrence
in univariate analysis were extra-com-
partmental site (p<0.01) and large size
(p<0.01), and both retained significance
in multivariate analysis (p<0.01 and
p=0.05, respectively). For the develop-
ment of metastases, extracompartmental
site (p<0.01), large size (p<0.01) and
high grade (p<0.01) were significant fac-
tors in univariate analysis, and they all
remained significant in multivariate
analysis (p=0.02, p<0.01 and p=0.01, re-
spectively). The estimated five-year dis-
ease-free survival rate was 63% and dis-
ease-specific overall survival rate 76%.
Non-favourable for disease-specific over-
all survival in univariate analysis were
extracompartmental site (p=0.02), large
size (p<0.01), high grade (p<0.01) and
advanced age of the patient (p=0.01),
and the three last mentioned retained
their significance in the multivariate
model (p<0.01, p=0.01 and p<0.01).
In upper extremity STS (Study III),
the prognostic factors for local recurrence
in univariate analysis were extracompart-
mental site (p<0.01) and extramuscular
or subcutaneous location with fascial
penetration (p=0.02). For the develop-
ment of metastases, extracompartmental
site (p<0.01), large size (p<0.01) and ex-
tramuscular or subcutaneous location
with fascial penetration (p=0.01) were
significant in univariate analysis. The esti-
mated five-year disease-specific overall
survival rate was 75%. Extracompartmen-
tal site (p=0.04) and large size (p=0.01)
were associated with fatal disease.
In STSs of the extremities, extracom-
partmental site was the strongest prog-
nostic factor for local recurrence, with
62% LRFS in the lower limbs and 69% in
the upper limbs, the total LRFS in limb
sarcomas being 65%. Extracompartmen-
tal site tumours had 56% MFS in ex-
tremity sarcomas. In Studies I and III,
91% (29/32) of the local recurrences oc-
curred in patients with extracompart-
mental tumours, and all amputations ex-
cept one were performed in this group.
LRFS for subcutaneous or intramuscular
tumours was 97% in extremity sarcomas.
In malignancies of the chest wall
(Study IV), nine out of 13 sarcoma pa-
tients (69%) and eight out of 10 breast
cancer patients (80%) died of their dis-
ease during the follow-up time. In the
subgroup of sarcoma patients, the sur-
vival rate was 54% at two years and 28%
at five years, whereas in the subgroup of
breast cancer patients the figures were
38% and 13%, respectively. The mean
survival time for patients with sarcomas
was 39 months (median 27 months,
range 5–83 months) and for those with
breast cancer 18 months (median 9
months, range 2–37 months). In the
subgroup treated with curative intention,
the survival rate was 65% at two years
and 38% at five years, with a mean sur-
vival time of 46 months (median 47
months, range 5–83 months). In the
subgroup of patients treated palliatively,
the figures were 30% and 0%, respective-
ly, with a mean survival time of 14
months (median 7 months, range 2–37
months).
1.4 Surgical margins
In sarcomas of the extremities (Studies I
and III), the most common treatments
were wide or compartmental surgery
without RT (38.7%) and marginal sur-
gery with RT (32.7%, Table 8). RT was
delivered to 43% of patients. The treat-
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Study I Study III
Local recurrence
    Number of local recurrences 18 (17%) 14 (17.5%)
    Median time to development of local recurrence, months (range) 24 (3-54) 16 (7-90)
Extracompartmental site <0.01 <0.01
Extramuscular or subcutaneous location with fascial penetration <0.01** 0.02
Large size <0.01 n.s.
Metastases
    Number of occurrences of metastases 32 (30%) 27 (34%)
    Median time to development of metastases, months (range) 20 (3-105) 17 (5-76)
Extracompartmental site <0.01 <0.01
Extramuscular or subcutaneous location with fascial penetration <0.01** 0.01
Large size <0.01 <0.01
High grade <0.01 n.s.
Disease-specific survival
Disease deaths 27 (25%) 18 (22.5%)
Extracompartmental site 0.02* 0.04
Extramuscular or subcutaneous location with fascial penetration 0.03** n.s.
Large size <0.01 0.01
High grade <0.01 n.s.
Advanced age 0.01 n.s.
The values are p-values in univariate analysis (95% confidence interval). In Study I, multivariate 
analysis was also performed.
*  = n.s. in multivariate model, significant in univariate model
** = result of univariate analysis, not introduced into multivariate model in original article
Table 7. Prognostic factors in Studies I and III for extremity soft tissue sarcomas
ment protocol was strictly adhered to in
74% of the patients, with local control of
86% of patients. In 26% of the patients,
treatment was considered inadequate,
with local control of 62%. The most
common reason for inadequate treat-
ment was omission of RT (16.7%) after
marginal excision owing to the patient’s
refusal of any further therapy, proximity
to wide margins or earlier RT. The sec-
ond most common reason was that re-
operation after an intralesional margin
was not performed because the patient
refused amputation. Therefore RT was
delivered to intralesional margins in
8.6% of patients. A wide or compart-
mental excision margin could be
achieved in 40.6% of the patients and a
marginal operation margin in 49.4%. In
9.7% of patients the intralesional margin
was left, because the patient refused to
have the amputation that would have
been required. The LRFS for intralesion-
al margins was 25% in the upper and
58% in the lower extremity, with disease-
free survivals of 25% and 33%, respec-
tively. In extracompartmental tumours
treated with a wide margin the five-year
LRFS was 77%, and in those treated with
a marginal margin and RT, it was 78%.
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Treatment            Study no.     
     I      %     III      %     total         %
Adequate 74 70 63 79 137 74
     Marginal + RT 29 27 32 40 61     32.7
     Wide 43 41 24 30 67     36.0
     Wide + RT 1 1 2 3 3       1.6
     Compartmental 0 0 5 6 5       2.7
     Compartmental + RT 1 1 0 0 1       0.3
Inadequate 32 30 17 21 49        26
     Intralesional 2 2 0 0 2       1.1
     Intralesional + RT 10 9 6 8 16       8.6
     Marginal 20 19 11 14 31     16.7
Total number of patients 106 80 186
RT = radiotherapy
In patients with full-thickness chest
wall malignancies (Study IV), postopera-
tive margins were analysed but not re-
corded, since analysis of surgical margins
was not the object of this study.
Thirty-four out of 40 dermatofibro-
sarcoma patients (Study V) underwent
only single primary or re-excision. In five
patients, re-excision had to be repeated
due to inadequate margins. One patient
had to be operated on three times at our
centre before the margins were adequate.
In all, 47 operations were required for the
40 patients to achieve adequate margins
(mean 1.2 stages per patient). The post-
operative margins achieved were wide in
11 patients, marginal in 28 and intrale-
sional in one patient. Gross margins were
recorded as the gross tumour-free mar-
Table 8. Treatment of limb sarcomas according to soft tissue sarcoma treatment pro-
tocol in Studies I and III
gins assessed by either the surgeon or the
pathologist. Gross margins were more
than 2 cm in 68% and more than 3 cm in
38% of patients. Histological margins ex-
ceeded 1.5 cm in 50% and 0.5 cm in 75%
of patients. In all patients, the mean
gross margin was 3.1 cm and the mean
histological margin 1.6 cm. The average
difference between gross and histological
margins was 1.5 cm. There were no sig-
nificant differences in margins between
different patient groups, except that his-
tological margins tended to be smaller in
the head and neck region (mean 0.7 cm)
than in other locations (mean 1.7 cm).
For primary tumours, 41% of patients
(13/27) needed reconstruction; for local
recurrences the proportion was 77% (10/
13).
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2. DNA copy number changes
between primary tumours and
local recurrences (Study II)
2.1 Overview of results and mean
number of changes
Sixty per cent (24/40) of all the samples
showed copy number aberrations. In 10
tumour pairs, the number of aberrations
was greater in local recurrences than in
primary tumours, although the histolog-
ical grade changed to more malignant in
only one tumour pair. In three pairs,
more aberrations were detected in pri-
mary tumours than in their local recur-
rences. In two pairs, the number of aber-
rations was equal in primary and locally
recurrent tumours. In five pairs, CGH
found no copy number changes in the
primary tumour nor in its local recur-
rence. These tumours were: two MFHs
(grade 3), two synovial sarcomas (grade
3) and one myxoid liposarcoma (grade
2). Of all the samples, CGH showed no
changes in 10 primary tumours and six
local recurrences.
Fifty per cent (10/20) of the primary
tumours showed copy number aberra-
tions. In local recurrences, copy number
aberrations were detected in 70% (14/
20) of the tumours. The total number of
aberrations in local recurrences was
more than twice that in primary tu-
mours. This increase in copy number
changes from primary tumours to local
recurrences was statistically significant
(p=0.02). The increase in gains from pri-
mary tumours to local recurrences was
also significant (p=0.03). The increase in
losses was without statistical significance.
The mean numbers of DNA changes are
presented in Table 9.
The mean number of changes dif-
fered between high-grade (grades 3 and
4) and low-grade (grades 1 and 2) tu-
mours. In primary tumours, the low-
and high-grade malignant sarcomas
showed an equal number of copy
number changes, whereas in local recur-
rences the mean number of changes was
more than twice as high in high-grade as
in low-grade tumours (Table 9).
Sarcomas can be grossly divided into
tumours with simple karyotypes and
specific genetic alterations (translocation
associated) and tumours with complex
karyotypes but no specific genetic altera-
tions (non-translocation associated).
The translocation-associated group
(n=4) had one myxoid liposarcoma and
three synovial sarcomas. The non-trans-
location-associated group (n=16) had
eight MFHs, three fibrosarcomas, two
leiomyosarcomas, one lipoma-like li-
posarcoma and two sarcomas NOS. In
the translocation-associated group, there
was no difference in the number of
changes between primary and locally re-
current tumours whereas in the non-
translocation-associated group the
number of changes was twice as high in
locally recurrent as in primary tumours
(Table 9).
2.2 Most frequent minimal
common regions of DNA
aberrations
The most frequent copy number change
was loss at 9p, with the minimal com-
mon region of 9p22-pter. This change
occurred in 30% of the local recurrences;
in only one (5%) primary tumour was a
loss affecting 9p21-pter detected. The
second most frequent copy number
changes were gains at 5p (minimal com-
mon region 5p14-15.1) and 20q, both of
which occurred in 25% of local recur-
rences. In primary tumours, there were
gains of 5p in 10% and of the entire
chromosome 20 in 5% of tumours. The
most frequent copy number changes that
affected primary tumours as well as local
recurrences with almost the same fre-
quencies were a gain at 7p with a mini-
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Table 9.  Mean number of changes in 20 tumour pairs analysed by comparative ge-
nomic hybridisation
mal common region of 7p12-pter in pri-
mary tumours (15%) and 7p11.2-pter in
local recurrences (20%) and losses of
13q21 and 8p12-pter (15% and 20%;
15% and 15%, respectively).
The most frequent high-level ampli-
fication at 18p11.3 was detected in 15%
of the local recurrences but in none of
the primary tumours. Recurrent high-
level amplifications were also seen at 17p
(primary tumours 5%, local recurrences
10%), 22q11.2 (local recurrences 10%),
1q21 (primary tumours 10%) and 1q21-
23 (local recurrences 5%).
2.3 Clonal relationship
Only two of the pairs in which both
samples had aberrations according to
CGH (n=9) shared identical aberrations,
although in one of them the length of
some aberrations had changed. One pair
did not have any common changes, and
in the remainder, common changes out-
numbered differences in two pairs and
differences outnumbered common
changes in two pairs. In two pairs, the
numbers of common changes and of dif-
ferences were identical.
        Primary tumours        Local recurrences  
 
All changes         2.45                 5.05                p=0.02 
Gains         1.45                 3.3                p=0.03 
Losses         1.0                 1.75                p=n.s. 
High level 
amplifications         0.4                 0.8 
 
Low grade (n=6)  
All changes         2.5                 2.8 
 
High grade (n=14)  
All changes         2.4                 5.8 
 
Translocation associated (n=4) 
All changes        0.25                 0.25 
 
Non-translocation associated (n=16) 
All changes        3.1                 6.3 
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DISCUSSION
1. Treatment protocol for
extremity soft tissue sarcomas
(Studies I and III)
Prevention of local recurrence of STS
has traditionally been, and still is, surgi-
cally the most important goal of treat-
ment. Local control rates ranging from
71% to 95% have been reported from
large sarcoma centres with modern treat-
ment (Table 3). A procedure that long
presented a surgical challenge was limb-
salvage, though this has now been widely
met. With conservative surgery com-
bined with RT, amputation rates from
4% to 30% have been reported, the rate
being between 10% and 20 % in most
tumour centres specialised in the man-
agement of STS. RT is often routinely
combined with conservative surgery.
In these studies we evaluated the
treatment and outcome of 186 patients
with STS of the extremities referred to
our hospital, which serves as the largest
tertiary referral centre for soft tissue tu-
mours and reconstructive surgery in Fin-
land. The objective has been to centralise
the treatment of STSs. Nevertheless,
many of the small, easily accessible pri-
mary tumours are still initially operated
on at district hospitals. The majority of
the patients in the studies had high-
grade tumours and patients referred for
local recurrence were also included. For
these reasons, our studies cannot be con-
sidered population based.
Our protocol, which comprises de-
tailed analysis of postoperative margins
and selective application of RT, seems to
be justified since the outcome of patients
is similar to that reported for earlier se-
ries (Coindre et al. 1996, Lohman et al.
2002). In our series, the estimated five-
year LRFS was 79%, MFS 70%, DFS 63%
and DSOS 76%. Our treatment protocol
proved its efficacy in local treatment.
The protocol was strictly followed in
74% of patients, with 86% local control
at five years. The most common reason
for protocol violation was omission of
RT. This implies that strict adherence to
the protocol would further reduce the
frequency of local recurrences. The sec-
ond most common reason for inade-
quate treatment was the patient’s refusal
of amputation after an intralesional op-
eration, an action that is more difficult
to interfere with. However, 90% of the pa-
tients maintained a functional limb. The
12.5% amputation rate for the upper ex-
tremity was slightly higher than that (9%)
for the lower extremity, although the me-
dian tumour size was smaller in the upper
than in the lower extremity (5 cm vs 7
cm). This reflects the fact that adequate
operation margins are more difficult to
achieve in the upper extremity owing to
the scantiness of soft tissues. There were
no significant differences in end-point
outcome measures between patients with
STS in the upper extremity and those
with STS in the lower extremity. Further,
with the exception of epitheloid sarcoma
(five patients), which occurred only in the
upper extremity, there was no difference
in histological diagnoses between the up-
per and lower extremities. Wide or com-
partmental (40.6%) or marginal (49.4%)
surgical margins could be achieved in
90% of patients.
Intracompartmental tumours, which
consist of intramuscular and subcutane-
ous tumours, had favourable local con-
trol (97%), an outcome that is consistent
with earlier results (Gibbs et al. 1997,
Rydholm et al. 1986). In this group of
patients, improvement in local treatment
is hardly needed, as intramuscular tu-
mours can usually be managed by myec-
tomy alone, as also found by other inves-
tigators (Rydholm et al. 1986). In
subcutaneous tumours not penetrating
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the fascia, wide excision is usually suffi-
cient treatment. In our experience, RT
should be delivered if postoperative mar-
gins are less than 2.5 cm.
The main factors determining tu-
mour resectability are the size and ana-
tomical location of the tumour. The
strongest prognostic factor for local re-
currence was extracompartmental site
with 65% local control in extremity sar-
comas; this factor was significant in both
upper and lower limbs. These tumours
comprised two-thirds of the extremity
tumours treated, and 91% of the local
recurrences occurred in this group. Thus
extracompartmental tumours constitute
the most frequent and challenging sub-
group in terms of local control. In extra-
compartmental tumours treated with
wide excision, local control was 77%,
suggesting that a margin of 2.5 cm may
not be sufficient for such tumours. Per-
haps the treatment protocol should be
altered to permit RT to be routinely de-
livered to all extracompartmental  tu-
mours, even in the event of wide exci-
sion margins. However, our result has to
be considered tentative only because of
the small number of patients; the issue
needs to be addressed within the context
of larger clinical trials. It has recently
been suggested by other authors, too,
that RT should be delivered to these tu-
mours more liberally, irrespective of ex-
cision margins (Trovik et al. 2001). Ef-
forts to improve treatment results should
be targeted mainly at this group of tu-
mours.
Large tumour size was significant for
local recurrence in STS of lower limbs
but lacked significance in upper limbs,
most likely due to the small sample size.
In upper limbs, the median tumour size
was smaller (5 cm vs. 7 cm in lower
limbs) and not sufficient to gain suffi-
cient statistical power. Large tumour size
is usually strongly (but not necessarily
always) associated with extracompart-
mental site. However, location in the
compartment may still be a more accu-
rate prognostic factor than tumour size
for local recurrence, because it has a
more direct effect on the extent of surgi-
cal margins and thus on the likelihood of
residual tumour.
High malignancy grade was not sig-
nificant for local recurrence in either
study. Although high histological grade
is generally considered a strong prognos-
tic marker for local recurrence, results
similar to ours have been reported else-
where (Cany et al. 1999, Pisters et al.
1996). This may indicate that tumour
compartmentalisation and size, which
determine surgical resectability, are more
important than malignancy grade for lo-
cal recurrence.
Surprisingly, the presentation status
(primary or local recurrence) did not
have prognostic significance for any of
the outcome measures, even in univari-
ate analysis. This is contrary to findings
in many earlier studies (Pisters et al.
1996, Zagars et al. 2003) and may be due
to the small proportion (18%) of pa-
tients referred with local recurrence and
thus to the lack of statistical power.
A strong association has been found
between positive surgical margins and
local recurrence (Herbert et al. 1993). In
our studies these factors were not in-
cluded in the statistical models for prog-
nostic significance. This omission is due
to our protocol, which states that no tu-
mour should be left with intralesional
margins (that is, “positive margins”).
Even so, some patients were left with int-
ralesional margins and, in them, local re-
currence-free survival was poor, 25% in
the upper and 58% in the lower extremi-
ty, with disease-free survival rates of 25%
and 33%, respectively.
The strongest prognostic factors for
the development of metastases were ex-
tracompartmental site and large tumour
size, both of which were significant in
upper and lower limbs. MFS in patients
with extracompartmental tumours was
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56%. High grade of the tumour was sig-
nificant for the development of metasta-
sis in lower limbs but not in upper limbs,
although a trend towards decreased MFS
was noted in high-grade tumours of the
upper limb (low grade 92% MFS vs. high
grade 63%). The lack of statistical power
is due to the larger proportion of high-
grade tumours in upper limbs (84%)
than in lower limbs (73%) and also to
the smaller sample size. These studies
demonstrate that tumour grade is a
strong factor predicting the development
of metastasis, as previously reported
(Pisters et al. 1996, Coindre et al. 1996).
The local recurrence rates in patients
treated with modern limb salvage meth-
ods are similar to those previously treated
with amputation. Efforts to improve the
outcome of patients with resectable STS
are now mainly focused on tumours with
negative prognostic factors. In terms of
local recurrence, these are extracompart-
mental high-grade tumours. The prefera-
ble method and sequencing of RT still re-
main to be established.  Adjuvant
chemotherapy may have a beneficial ef-
fect on local as well as on distant recur-
rence (Sarcoma Meta-Analysis Collabora-
tion 2000), and a randomised multi-
centre trial (Issels et al. 2002) has been set
up to answer these questions. New opera-
tive techniques have been introduced to
further reduce the number of amputa-
tions (Matsumoto et al. 2002). In the fu-
ture, advances in microsurgical tech-
niques in parallel with molecular
biological discoveries may resolve prob-
lems related to major nerve regeneration
(Siemionow et al. 2004) while novel
methods, such as isolated limb perfusion
with TNF and melphalan, may improve
local control in tumours with poor prog-
nosis. However, until definitive molecu-
larly targeted treatment to change the
natural history of STS is available, even
absolute local control is not likely to re-
solve the problem of distant dissemina-
tion. As treatment strategies for STS con-
tinue to be refined, probably the most im-
portant factors for improving the out-
come of sarcoma patients are to minimize
diagnostic and treatment failures and to
avoid delays in treatment. These goals are
best achieved by the centralisation of de-
finitive treatment and by the provision of
nationwide information about primary
diagnostics and referral practice.
2. DNA copy number changes
in local recurrences (Study II)
In this study we conducted a genome-
wide survey of primary STS and local re-
currences by CGH. Fifty per cent of the
tumour pairs showed more aberrations
in the locally recurrent than in the pri-
mary tumour. A more than two-fold in-
crease in the number of copy number
aberrations was detected in local recur-
rences although there was no change in
histopathological grade in 19 out of 20
tumour pairs. These findings suggest
that tumour progression from primary
to locally recurrent STS may be associat-
ed with an increase in genetic changes
and that local recurrences are thus more
advanced than primary tumours. Genet-
ic progression has also been noted in re-
lapses of intra-abdominal STS (Weng et
al. 2005). An increased number of aber-
rations has also been detected in large
Merkel cell carcinomas with a higher risk
of distant metastasis than small tumours
(Larramendy et al. 2004). Nevertheless,
in our study, the copy number karyo-
type, a gain of chromosome 2, of one
primary synovial sarcoma remained
identical, also in the local recurrence,
over a period of 32 months.
In our study, gains predominated
over losses in primary tumours with a
ratio of 3:2. A similar trend was detected
in local recurrences, with a ratio of 13:7.
The number of high-level amplifications
was twice as high in local recurrences as
in primary tumours. The most common
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copy number change, a loss at 9p with
the minimal common region 9p22-pter,
occurred in 30% of the local recurrences
but in only 5% of the primary tumours.
Thus a clear increase in the losses at 9p
was noted in local recurrences as com-
pared with primary tumours. 9p losses
are reported to be as common in prima-
ry sarcomas as in their metastases
(Tarkkanen et al. 1999) but they are also
frequent in various human neoplasms
(Knuutila et al. 1999).
 Gains at 5p were relatively common,
being found in 10% of primary tumours
and in 25% of local recurrences. High-level
amplifications at 5p were also noted but
these were not recurrent. Gains and high-
level amplifications at 5p are often seen in
sarcomas and carcinomas of different sub-
types (Knuutila et al. 1998). The increase
in gains was also detected at 20q, occurring
in 5% of the primary tumours and in 25%
of the local recurrences. High-level ampli-
fication in 18p was detected in three local
recurrences but in none of the primary tu-
mours. The histopathological diagnosis for
these recurrences was two MFHs and one
fibrosarcoma.
Quantitative changes, for example,
those in which a gain changed into a
high-level amplification or in which the
length of a change increased, occurred in
several tumour pairs. It was also noted
that an aberration in one of the samples
appeared as a “trend” in the other sample
but did not exceed the thresholds for
gain or loss. Similar observations have
previously been made in primary sarco-
mas and their pulmonary metastases
(Tarkkanen et al. 1999).
Some degree of clonal relationship
was detected in eight of the nine tumour
pairs with aberrations in both samples,
in agreement with observations made in
sarcoma metastases (Tarkkanen et al.
1999). In one tumour pair, primary tu-
mour and local recurrence were geneti-
cally completely different. In metastatic
renal cell carcinomas, a high probability
of a common clonal progenitor was
found in 58% of the patients, but 32% of
the metastases were genetically almost
totally different from the primary tu-
mour (Bissig et al. 1999).
Comparative genomic hybridisation
detected no changes in 16 samples. Of
these, 15 were paraffin-embedded sam-
ples and one was a freshly frozen tissue
sample, so it is not likely that the normal
copy number karyotype was due to a
non-representative sample. A possible
explanation for the normal finding
might be intratumoural variation with
multiple subclones. CGH detects only
clonal changes. Aberrations in subclones
may balance one another, thus giving a
normal result by CGH. It is also possible
that the copy number aberrations were
too small to be detected by CGH. More-
over, since CGH does not detect bal-
anced aberrations, a tumour with only a
specific translocation will appear normal
according to CGH, which may explain
why no aberrations were detected by
CGH in some cases. Normal karyotypes
have been reported in metastases of Ew-
ing sarcoma (Brisset et al. 2001) and also
in metastases of synovial sarcoma and
MFH (Tarkkanen et al. 1999).
Although specific alterations in local
recurrence were not detected, our study
confirms that an increasing number of
DNA sequence copy number aberrations
is a dominant feature in the progression
from a primary tumour to a local recur-
rence.
3. Reconstructions in
musculoskeletal tumour
surgery (Studies I, III–V)
When amputations without free flap re-
constructions were excluded from the
total, reconstructions were required in
53% of the patients. The most common
reconstruction was a free flap, which was
required in 22% of all patients and in
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15% of those with the extremity STSs.
The second most common reconstruc-
tion was a skin graft, followed by pedi-
cled muscle flaps and skin flaps. The suc-
cess rate for the 56 free flaps was 96.4%,
which is similar to results from other
centres (Cordeiro et al. 1994, Kroll et al.
1996, Hidalgo et al. 1998). Note that the
high rate of plastic surgical reconstruc-
tions in this series reflects the complicat-
ed referral pattern of our tertiary referral
centre, where free flaps are probably
overrepresented. The high rate of recon-
structions also implies that all-inclusive
treatment of musculoskeletal tumours
requires considerable application of plas-
tic surgical methods. Wide excision of a
large, extracompartmental STS is seldom
possible without adequate reconstruc-
tion. Even in dermatofibrosarcomas, re-
constructions were used for more than
half of the patients.
The possibility of using adjuvant
treatments must be taken into account
when planning the surgery. The operation
should be planned to minimise the prob-
ability of wound complications, such as
wound dehiscence, infection and seroma
formation, and to enable RT and chemo-
therapy, if required, to be delivered with-
out delay. Wound complications are com-
monly minimised with flap reconstruc-
tions. Particularly important is that the
flaps allow tension-free closure and good
perfusion in wound edges. Muscle and
musculocutaneous flaps provide abundant,
well vascularised tissue for the operation /
radiation area filling the cavities. By selec-
tive combination of RT and surgery, the
unnecessary morbidity associated with RT
can be avoided (Yang et al. 1998). Omitting
RT in cases in which it is not actually need-
ed enables the safe use of skin grafts in re-
construction (Bui et al. 2004). This reduces
the number of unnecessary microvascular
flaps and thus lowers the cost of treatment.
However, there should be no doubt about
delivering RT if excision margins remain
inadequate.
The choice between free and local /
pedicled flaps depends very much on the
anatomic region to be restructured
(Hidalgo et al. 1998). In the thigh area,
flaps are not usually needed due to the
abundance of soft tissues. In the proxi-
mal upper limb, pedicled LD is a good
option and was used in nine patients
(11%). In the knee or proximal lower
leg, pedicled gastrocnemius is available
and was used in eight patients (7%). If
the re-excision demands large resection
or the tumour is located in the middle or
distal upper extremity or distal lower ex-
tremity, wide excision is not usually pos-
sible without free flap reconstruction.
The role of reconstructive surgery is even
more pronounced after tumour excision
in the upper limb than elsewhere in the
body, since excision is more likely to
cause tendon and nerve defects and thus
severe functional deficiencies.
The selection of a free flap for onco-
logical musculoskeletal reconstruction
has to take all the traditional aspects,
such as aesthetic and functional result,
donor site morbidity and technical feasi-
bility, into account. Also important is the
reliability of the flap (Kroll et al. 1996).
In this series, only five different types of
free flap, namely TFL (n=22), LD
(n=20), radial forearm (n=5), fillet ex-
tremity (n=3) and TRAM (n=3), were
needed to reconstruct most of the de-
fects. Thus, these flaps accounted for
95% of all the free flaps used. The TFL
free flap was mainly used for chest wall
reconstructions (21/26). LD was most
frequently used in the extremities (18/
29); in the lower extremity it was capable
of solving nearly all problems (16/18 free
flaps). Radial forearm free flap was used
only in the upper extremity and was the
free flap most commonly used in that
site (5/11). It is obvious that selection of
these methods for reconstruction reflects
the experience accumulated in our insti-
tution with these particular flaps. It has
been reported that only a few flap types
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comprise the armamentarium needed to
reconstruct most cases (Hidalgo et al.
1998). However, all the flaps we used,
possibly excluding fillet flaps, are consist-
ent, reliable and regularly used by recon-
structive microsurgeons (Salemark et al.
1991, Kroll et al. 1998).
  Certain points have to be taken into
account in the selection of flaps for chest
wall reconstruction. In the event of flap
loss or major wound complications, the
vital intrathoracic organs will be ex-
posed, leading to life-threatening com-
plications (Cordeiro et al. 2001). Thus
the reliability of the flap is even more
pronounced in the chest wall than in
other regions. The ideal flap has a con-
stant anatomy and a reliable and suffi-
ciently large pedicle. Its composition is
versatile, and it preferably provides me-
chanical support, too. It has resistance
against infection owing to the common
use of synthetic materials and rib-grafts
in these operations. Further, it should be
possible to harvest the flap quite rapidly
with the patient in either the supine or
the lateral position, thus avoiding major
postural changes during the operation.
Moreover, donor site morbidity should
be acceptable and in proportion to the
indication. The defect is often large,
since it is important to excise as much of
the unhealthy or radiated tissue as possi-
ble (Arnold et al. 1996). Thus a flap of
considerable size may be required. Mul-
tiple pedicled flaps have traditionally
been used for the reconstruction of large
(average 428 cm2, 21×21 cm) defects
(Chang et al. 2004). If the defect affects
only one pleural cavity, it is not advisable
to disturb the healthy side by needlessly
harvesting a flap, e.g. latissimus dorsi
with an extensive skin island, or rib graft.
Such procedures may further impair the
patient’s respiratory function, and so
prolong, or even prevent, recovery. In
this sense, one large free flap harvested
from a distant site might be safer than a
pedicled flap that would result in a do-
nor site with morbidity at or close to the
chest area.
 The musculocutaneous TFL flap
surface area can be up to 1400 cm2
(35×40 cm) and it can include the rectus
femoris muscle if abundant muscle tis-
sue is needed, e.g. to cover a bronchop-
leural fistula or to fill the chest cavity af-
ter empyema. The pedicle is under the
flap (not outside as in the latissimus dor-
si), a location usually well suited to the
anatomy of the defect. The pedicle is
large and long (Heitmann et al. 2000),
and it can be further extended by includ-
ing the descending branch of the lateral
circumflex femoral artery. This manoeu-
vre is performed with very large flaps; if
necessary, even one of the motor nerve
branches to the vastus lateralis muscle
may be divided (and reconstructed) in
order to obtain optimal pedicle vessels.
We did not lose any TFL flaps, which
proved to be very reliable, despite the use
of a saphenous vein loop in seven of the
22 flaps. The temporary arteriovenous
loop method has been successfully ap-
plied in reconstructions of the extremi-
ties (Lin et al. 2004 ), trunk (Earle et al.
1990, Karanas et al. 1998) and head and
neck region (Kim et al. 1998), and in our
series it was a valuable tool in full-thick-
ness chest wall reconstructions. Anasto-
mosing the pedicle to intraperitoneal
vessels has also been documented
(Chevray et al. 2003). We intentionally
avoided this procedure since, in the event
of reoperation, the stabilising recon-
structions would have been opened and
the peritoneal and thoracic cavity ex-
posed repeatedly, thus increasing the risk
of hernias or pedicle compression. The
strong fascial portion of the TFL flap
gives additional stability to the recon-
structed chest wall and it can be sutured
tightly to prevent air leakage. We consid-
er TFL especially suitable after forequar-
ter amputation if the fillet extremity flap
cannot be used. Clearly, the widest TFL
donor sites cannot be closed primarily,
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and then a skin graft cover is used. As the
donor site is in the thigh, harvesting a
TFL flap does not affect the patient’s res-
piratory function. TRAM also makes a
large, reliable and constant flap. In suita-
ble patients, donor site morbidity (pain,
tension and respiratory effect) may be
acceptable, but in very slim patients the
flap is of limited size. It has also been
demonstrated in breast reconstructions
that elevation of a TRAM flap increases
intra-abdominal pressure (Losken et al.
2002). The effect on respiratory function
when the TRAM flap is used for chest
wall reconstructions may be considera-
ble, especially in patients with advanced
disease treated with several therapies and
in a catabolic state.
In our series we had one forequarter
and five extended forequarter amputa-
tions. All the extended forequarter am-
putations required a large free flap. Rem-
nant forearm was used in two patients
and TFL in three. If extended forequarter
amputation or hemipelvectomy is to be
performed, the fillet extremity is usually
the first option for the free flap, assum-
ing that the flap and the pedicle area
(distal brachial or popliteal vessels) are
tumour free (Tran et al. 2000, Cordeiro
et al. 2001). In two Tikhoff-Linberg re-
sections, one was closed directly and the
other with a LD free flap. We emphasise
that in extremely radical and mutilating
procedures such as forequarter amputa-
tion or hemipelvectomy the possible cur-
ativity of the operation should not be
compromised by the limited reconstruc-
tive options available.
4. Surgical treatment of chest
wall tumours (Study IV)
Full-thickness chest wall resection with
microsurgical reconstruction is one of
the most challenging procedures in re-
constructive surgery today. It has to be
emphasised, however, that the free flap
method is not routine for chest wall re-
construction. The group of patients de-
scribed here is highly selected and consti-
tutes a small fraction of all patients with
chest wall resection. The chest wall defects
of most patients can be reconstructed
with conventional methods such as local
or pedicled flaps (Mansour et al. 2002). A
free flap is only indicated when conven-
tional flaps are not available or they are
too small. Moreover, in small defects, sta-
bilisation of the chest wall is not manda-
tory (McCormack 1989).
Patients with chest wall tumours of-
ten present with advanced disease and
compromised general condition, and
their tolerance of complications is im-
paired. Careful individual evaluation to
appraise the risks and benefits is impor-
tant. Even a minor problem may lead to
major systemic complications, such as
infection of the prosthetic material,
mesh removal or pulmonary dysfunction
(Cordeiro et al. 2001). Because two ex-
tensive operations are combined, with an
average operation time of seven hours, a
two-team approach (tumour resection
and free flap harvest) is necessary to
shorten the duration of these operations.
At the beginning we did not use for-
eign materials or free rib grafts in our pa-
tients, because they have been associated
with deep infections, albeit infrequently
(Deschamps et al. 1999). However, it be-
came evident that stability is crucial in the
early postoperative period, when the pa-
tient is being extubated. In one patient
with extended forequarter amputation,
the unstable chest wall prevented sponta-
neous breathing. A new operation, in
which rib grafts were placed under the
flap, was performed and the patient re-
covered. Thereafter, we began to use syn-
thetic mesh and rib grafts more liberally.
Our decision to do so is borne out by ear-
lier studies reporting that the use of syn-
thetic mesh or rigid prosthesis reduced
ventilator dependence (Nash et al. 1991,
Kroll et al. 1993). The rib grafts were al-
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ways harvested from the resection side (if
not sternal) to avoid morbidity on the
healthy side. Inferior ribs were preferred
and no adjacent ribs were harvested. In
thoracoabdominal resections, the dia-
phragm was sutured back to its original
position or reconstructed with synthetic
material (PTFE). In our experience, bony
stability is particularly important in pa-
tients who have a defect after sternal exci-
sion, high lateral resection or extended
forequarter amputation.
Surprisingly, there were no deep in-
fections in this series even though the tu-
mours were often infected, ulcerated,
and irradiated. Thus shield prostheses of
methylmethacrylate could probably be
used safely to stabilise the chest wall. The
primary target of such prostheses would
be the sternal area, where rib grafts are
not easily available. It has been claimed
that free flaps should not be used in the
presence of infection (Al-Kattan et al.
1995). Our results contradict this con-
clusion, since the absence of deep infec-
tions in our patients may reflect the im-
portance of well-vascularised flap tissue
covering the defect, without the tension
and vascular compromise often seen in
pedicled flaps of limited size and range.
Perioperative mortality was 0-17%
in a recent series of chest wall resections
(Cordeiro et al. 2001, Arnold et al. 1996,
Mansour et al. 2002, Al-Kattan et al.
1995, Cohen et al. 1996). Our results im-
ply that extensive chest wall resections
with microvascular reconstructions are
relatively safe. Although long-term sur-
vival is poor, especially in breast cancer
patients, the procedure may offer them
considerable palliation (Vandeweyer et
al. 2002, Downey et al. 2000, Dahlstrom
et al. 1993). However, in the proximal
sternal area, where major vessels and
phrenic nerves are particularly vulnera-
ble during resection, it may not be sensi-
ble to perform a full-thickness resection
if the nature of the operation is pallia-
tive. Long-term survival is better in sar-
coma patients, and in them the resec-
tions may even be curative, which is con-
sistent with the findings of earlier studies
(Walsh et al. 2001). In STS patients, an
intralesional operation must be avoided
at all costs, because it leads to dissemina-
tion of the disease into pleural cavities.
In curatively intended treatment, the ex-
tent of the tumour resection should not
be compromised by the size of the local
or pedicled flaps available. To achieve
wide resection margins in local disease,
microvascular reconstructions should
perhaps be used more liberally in sarco-
ma patients.
5. Treatment protocol for der-
matofibrosarcoma (Study V)
In this series, 40 patients with dermatofi-
brosarcoma protuberans (DFSP) were
treated by surgical excision, with no re-
currences during the follow-up. The
wide range of the results of wide excision
in the literature is probably due to the
vagueness of the term “wide excision”,
which is generally defined as an excision
with 2–3-cm gross margins and histolog-
ically “negative” margins. Previous re-
ports document that increasing the gross
margin decreases the local recurrence
rate (Roses et al. 1986, Bowne et al.
2000). However, due to the infiltrative
growth pattern with fingerlike-projec-
tions in DFSP, it is not likely that even
the most careful histological examina-
tion would be able absolutely to preclude
intralesional operation when histological
margins are short. To improve local con-
trol, more exact recommendations con-
cerning the length of histological tu-
mour-free margins are therefore prob-
ably needed.
Our study demonstrates that good lo-
cal control can be achieved with repeated
excisional surgery. The clinical assess-
ment of an adequate surgical margin is
extremely difficult. The mean gross mar-
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gin in our patients was 3.1 cm but histo-
logically it was 1.6 cm. The average differ-
ence between gross and histological mar-
gins was 1.5 cm, with a broad range. A
histological tumour-free margin averag-
ing 1.6 cm was sufficient for complete lo-
cal control. In a recent series of 60 pa-
tients, a minimum histological tumour-
free margin of 1 cm yielded a five-year re-
currence rate of 14% (Chang et al. 2004).
However, in a study of patients operated
on with Mohs surgery, a sole 3-cm-wide
gross margin would have left 15.5% of the
tumours inadequately excised (Ratner et
al. 1997). It is thus emphasised that, after
a so-called wide excision, the postopera-
tive margin should always be verified by
careful histological examination whatever
the extent of the gross margins.
The main advantage of excisional sur-
gery over micrographic surgery is that it is
time saving. In micrographic surgery,
subsequent operations are often needed
due to inadequate excision or for recon-
struction of a primary defect that was left
open. In an earlier series of 58 patients
treated with micrographic surgery, the
mean number of stages was 2.4, with a
range of 1–8 (Ratner et al. 1997). In a
randomised study of basal cell carcinoma,
no significant differences in local recur-
rence rates were noted between excisional
and Mohs surgery, but the costs were al-
most twice as high in the latter (Smeets et
al. 2004). In our series, the mean number
of stages was 1.2, with a range of 1-3,
which demonstrates that the number of
operations needed in Mohs surgery is
twice that in excisional surgery.
In cases in which the tumour infil-
trates the deep fascia or muscle, especial-
ly in local recurrences that may have
been operated on several times, all ef-
forts should focus on aggressive and
wide removal of the tumour, since recur-
rence will usually lead to mutilating op-
erations some time in the future. If flap
reconstructions are performed, there
should be no doubt about the adequacy
of the excision, as flaps may prevent the
early detection of a local recurrence.
Wide excision and primary reconstruc-
tion in one stage can be performed on
most patients, with good functional and
cosmetic results. In the head and neck
region, histological margins were shorter
(mean 0.7 cm) than in other locations
(1.7 cm). In these areas, where extensive
margins usually cause greater morbidity,
micrographic surgery may be a valuable
tool, particularly for primary tumours.
Our treatment policy is that when a his-
tological margin is less than 1.5 cm a re-
operation is usually performed. Howev-
er, if the re-operation would severely
impair the functional or cosmetic result,
more scarce margins may be accepted,
and patients are carefully followed. Even
an intralesional margin may then be ac-
cepted in non-fibrosarcomatous cases,
since DFSP typically grows slowly and
the risk of fibrosarcomatous differentia-
tion and the development of metastases
is relatively low. In the future, imatinib
could perhaps be used as an adjuvant
therapy in patients in whom it is impos-
sible to achieve sufficient surgical mar-
gins with conservative surgery (Sirvent
et al. 2003, McArthur et al. 2005).
The local aggressiveness of the dis-
ease poses a challenge in the treatment
of DFSP. Extensive operations may be re-
quired, but with current treatment the
prognosis is good and curative treatment
usually possible. Reconstructive proce-
dures are frequently needed, even in pri-
mary tumours. The extent of the resec-
tion should not be compromised by the
reconstructive options available. In local-
ly recurrent DFSP, most patients (77%)
needed a skin-graft or a flap due to a
large tissue defect. Thus it is emphasised
that coordination of the treatment of
dermatofibrosarcomas should be cen-
tralised in institutions with expertise in
the treatment of musculoskeletal tu-
mours and reconstructive surgery.
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SUMMARY AND CONCLUSIONS
1. The limb-salvaging treatment proto-
col for STS is functioning well and it
should be strictly followed.
2. Tumours located extracompartmen-
tally have the poorest prognosis and
should be the main target of efforts
to improve treatment strategies. RT
may be of value to all deep extracom-
partmental tumours.
3. Reconstructive procedures are suc-
cessful and frequently needed in STS
surgery. Tumours should be operated
on at centres where all plastic surgical
reconstruction options are available.
4. Owing to tumour progression, the
number of genetic changes studied
by CGH is increased in local recur-
rences.
5. Large microvascular reconstructions
for full-thickness defects of the chest
wall are possible with acceptable re-
sults. The TFL free flap is well suited
to chest wall reconstruction. In STS,
the operation may be curative and in
breast cancer it may offer valuable
palliation.
6. Good local control can be achieved in
the majority of patients with der-
matofibrosarcoma in one operation,
as long as excision is not compro-
mised by the limited number of re-
constructive surgery options availa-
ble.
The studies discussed here evaluated a
wide variety of surgical procedures for
musculoskeletal malignancies, the ma-
jority of them STS. Plastic surgical re-
constructions were needed in more than
half of the cases. The success rate of
these procedures was good, even when
combined with oncological treatment.
Although some surgical procedures were
infrequent even in this highly selected
patient material, five different types of
free flap were capable of solving 95% of
the reconstructive problems. The free
flap most commonly used in the lower
extremity was LD, in the upper extremity
radial forearm flap and in the chest wall
TFL.
The extremity STS patients treated
with the HUCH protocol were evaluated.
The protocol, which aims to spare limbs
through a selective combination of sur-
gery and RT, was found to function well
in terms of limb salvage rate and onco-
logical outcome measures. Subcutaneous
and intramuscular tumours can fre-
quently be managed by surgical treat-
ment alone. Tumours penetrating the
deep or muscle fascia and those located
extra-compartmentally have the poorest
local control despite wide surgery with
2.5-cm microscopic margins; patients
with such tumours might be the main
target for adjuvant therapies. Some pro-
posals for even better results were made.
One was the delivery of RT to deep ex-
tracompartmental tumours despite wide
excision margins. Another was strict ad-
herence to the treatment protocol in the
future. In most of the protocol viola-
tions, RT was omitted after marginal sur-
gery or amputation was not performed
after an intralesional operation.
An analysis of 20 cases of primary
STS and their subsequent local recur-
rence according to CGH revealed an in-
crease in copy number changes in local
recurrences due to tumour progression.
Gains predominated over losses. Loss at
9p and gains at 5p and 20q were more
frequent in local recurrences, and high-
level amplification of 18p11.3 was only
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detected in local recurrences. Although
no alteration specific to local recurrence
was found, these alterations may repre-
sent changes that are important during
STS progression.
The operative techniques used in pa-
tients with chest wall malignancy requir-
ing extensive full-thickness resection
were evaluated. Important factors con-
cerning flap selection, stabilisation of the
chest wall and selection of patients were
reported, thus helping the planning of
operations. The lack of infectious com-
plications, even after synthetic mesh and
free rib graft reconstructions, may reflect
the importance of well-vascularised flap
tissue coverage. Information about pa-
tient outcome was gathered, leading to
the conclusion that the operation is pal-
liative for breast cancer, even after maxi-
mal extent of resection, but that it may
be curative for sarcomas. The TFL free
flap was found to be reliable in full-
thickness chest wall reconstruction in
our series, which, to our knowledge, is
the largest series reported.
In the treatment of dermatofibrosar-
comas, we demonstrated that clinical
margin assessment is extremely difficult.
A gross margin averaging 3.1 cm resulted
in a 1.6-cm histological, tumour-free
margin. Hence, postoperative histologi-
cal margins should be evaluated with
care and as meticulously as in other
types of STS. A histological margin of
1.6 cm was sufficient for complete local
control, and is therefore suggested as a
treatment guideline. Most tumours were
surgically excised in one operation.
In conclusion, our results for treat-
ment of STS are consistent with the find-
ings of other tumour centres, and demon-
strate that limb-sparing surgery and a
selective combination of treatment mo-
dalities give good local control and ac-
ceptable survival. It is emphasised that no
routine solutions exist for the treatment
of musculoskeletal malignancies. Surgi-
cally, these tumours are characterised by
their variable location, and by the wide
spectrum of ablative procedures and the
extensive amount of reconstructions re-
quired. Surgical and oncological treat-
ments are combined and planned for each
patient individually. As efforts continue to
refine treatment strategies and adjuvant
therapies for musculoskeletal malignan-
cies, STS in particular, the most impor-
tant factor for the outcome of these pa-
tients is that their treatment should be
concentrated in specialist centres, where
adequate diagnostics, surgery and adju-
vant treatments can be undertaken at the
primary stage. In the treatment of these
malignancies, plastic surgical reconstruc-
tive procedures are an essential part of
surgery and should be readily available.
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